19th Ave New York, NY 95822, USA

Vaccines

Vaccines

health.go.ke

COVID-19: Another 407,000 doses of AstraZeneca vaccine arrive in Kenya

Source: KMoH

Kenya’s quest to vaccinate her entire adult population received a shot in the arm on Tuesday after a further 407,000 doses of the Astrazeneca Covid-19 vaccine arrived in the country....

jwatch.org

Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine in Pregnant Women

Source: NEJM

Report on peer review article It's important to note that the cases in this study included asymptomatic and symptomatic infections, which partially explains the somewhat lower effectiveness that was observed....

jwatch.org

Gauging the Effectiveness of SARS-CoV-2 Vaccines

Source: NEJM

Report on peer review article This large population-based study confirms just how effective the SARS-CoV-2 mRNA vaccines can be for preventing SARS-CoV-2 infection. The investigators did not assess effectiveness for...

jwatch.org

More on Myocarditis and Pericarditis after COVID-19 Vaccination

Source: NEJM

Report on peer review article Although a temporal association does not establish causation, the incidence rates of diagnosed myocarditis and pericarditis during COVID-19 vaccination were more than 60% higher than...

nejm.org

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents

Source: NEJM

Peer review article The mRNA-1273 (Moderna) vaccine had an acceptable safety profile in adolescents. The immune response was similar to that in young adults, and the vaccine was efficacious in...

nejm.org

Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers

Source: NEJM

Vaccinated health care workers can be infected with variants of concern transmitted from unvaccinated household contacts and may transmit SARS-CoV-2 in the hospital if not screened early enough. Finally, variants...

nejm.org

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis

Source: NEJM

Peer review article The high mortality associated with VITT (blood clotting events) was highest among patients with a low platelet count and intracranial hemorrhage. Treatment remains uncertain, but identification of...

thelancet.com

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

Source: Lancet

Peer review article The heterologous ChAdOx1 nCov-19– (Oxford/AstraZeneca) BNT162b2 (Pfizer-BioNTech) immunisation with 10–12-week interval, recommended in Germany, is well tolerated and improves antibody production compared with homologous ChAdOx1 nCov-19 vaccination...

thelancet.com

Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5–6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis

Source: Lancet

Peer review article Single doses of either BNT162b2 (Pfizer-BioNTech) or ChAdOx1 nCoV-19(Oxford/AstraZeneca) in older people induces immunity in most participants, and is markedly enhanced by previous infection. Cellular responses were...

thelancet.com

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

Source: Lancet

Peer review article ChAdOx1 nCoV-19 (Oxford/AstraZeneca) was well tolerated, showing favourable safety and immunogenicity in people with HIV, including heightened antibody production in SARS-CoV- participants. People with HIV showed cross-reactive...

thelancet.com

Extending the interval of COVID-19 vaccine regimens in individuals aged 80 years or older

Source: Lancet

Exactly how extended-interval dosing might protect against future variants of concern is an important consideration and additional studies could help to better define dose regimens in people aged 80 years...

thelancet.com

Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study

Source: Lancet

Peer review article History of SARS-CoV-2 infection impacts the magnitude and quality of antibody response after a single dose of COVID-19 vaccine in long term care facilities residents. Residents who...

thelancet.com

Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study

Source: Lancet

Peer review article History of SARS-CoV-2 infection impacts the magnitude and quality of antibody response after a single dose of COVID-19 vaccine in long term care facility residents. Residents who...

thelancet.com

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination

Source: Lancet

Safety considerations associated with the Oxford–AstraZeneca COVID-19 ChAdOx1-S vaccine (AZD1222) have led many public health agencies to recommend a heterologous boost, with a different mRNA vaccine after prime vaccination with...

bmj.com

Profiteering from vaccine inequity: a crime against humanity?

Source: BMJ

Pfizer announced an intention to profit from its Covid-19 vaccine. In the first three months of 2021, Pfizer’s vaccine brought in $3.5bn (£2.5bn; €3bn) in revenue and hundreds of millions...

bmj.com

Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study

Source: BMJ

Peer review article Vaccination with CoronaVac (Sinovac Biotech) was associated with a reduction in symptomatic Covid-19, hospital admissions, and deaths in adults aged ≥70 years in a setting with extensive...

bmj.com

Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study

Source: BMJ

Peer review article Two doses of mRNA covid-19 vaccines were observed to be highly effective against symptomatic infection and severe outcomes. Vaccine effectiveness of one dose was observed to be...

bmj.com

Covid-19: FDA set to grant full approval to Pfizer vaccine without public discussion of data

Source: BMJ

Transparency advocates have criticised the US Food and Drug Administration’s (FDA) decision not to hold a formal advisory committee meeting to discuss Pfizer’s application for full approval of its Covid-19...

bmj.com

Covid-19 booster vaccines: What we know and who’s doing what

Source: BMJ

The virulence of the delta variant has prompted many countries to start administering booster vaccines. Many high and middle income countries have been discussing booster doses (a third dose, in...

bmj.com

Covid-19: Two vaccine doses are crucial for protection against delta, study finds

Source: BMJ

The two-dose regimen of the Pfizer-BioNTech Covid-19 vaccine is 88% effective against symptomatic disease caused by the Delta variant, while the Oxford-AstraZeneca vaccine is 67% effective, research has found.

cdc.gov

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021

Source: US CDC

Continued COVID-19 vaccination will prevent COVID-19 morbidity and mortality far exceeding the expected cases of Guillain–Barré syndrome (a rapid-onset muscle weakness), Thrombosis thrombocytopenia syndrome (blood clotting issues) and myocarditis (inflamation...

cdc.gov

COVID-19 Science Update released: August 13, 2021 Edition 102

Source: US CDC

Report on 2 peer review articles and 6 pre-release peer review articles Peer review article Although COVID-19 duration is usually short in children, some children experience prolonged illness. SARS-CoV-2 variants...

cdc.gov

Investigation of Long-Term Effects of Myocarditis after mRNA COVID-19 Vaccination

Source: US CDC

CDC is actively investigating reports of people developing myocarditis (inflammation of the heart muscle) after receiving a mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna). Most of these people fully recover, but...

africacdc.org

Africa Trade Insurance Agency supports Africa CDC in COVID-19 Response in Africa

Source: Africa CDC

Africa is facing a surging third wave of the COVID-19 pandemic and vaccination remains a challenge. As a partner in the continents’ response to the pandemic, The African Trade Insurance...

cdc.gov

COVID-19 Science Update released: August 20, 2021 Edition 103

Source: US CDC

Report on 4 peer review articles and 2 prerelease peer review articles Adolescents vaccinated with 2 doses of mRNA-1273 (Moderna) had immunogenicity and vaccine efficacy comparable to young adults, with...

who.int

Interim statement on dose-sparing strategies for COVID-19 vaccines (fractionated vaccine doses)

Source: WHO

While SAGE acknowledges the potential public health benefits of dose-sparing strategies to increase vaccine supply and accelerate population-level vaccination coverage, SAGE considers there is currently insufficient evidence to recommend the...

who.int

Medical Product Alert N°5/2021: Falsified COVISHIELD vaccine

Source: WHO

This WHO Medical Product Alert refers to falsified COVISHIELD ChAdOx1 nCoV-19 (Oxford/AstraZeneca) Corona Virus Vaccines (Recombinant)) identified in the WHO African Region, and the WHO South-East Asia Region. The falsified...

who.int

Interim statement on COVID-19 vaccine booster doses

Source: WHO

In the context of ongoing global vaccine supply constraints, administration of booster doses will exacerbate inequities by driving up demand and consuming scarce supply while priority populations in some countries,...

who.int

Interim statement on heterologous priming for COVID-19 vaccines

Source: WHO

WHO with support of the Strategic Advisory Group of Experts (SAGE) on Immunization and its COVID-19 Vaccines Working Group is reviewing the emerging evidence on the use of heterologous priming...

afro.who.int

Learning from Botswana’s COVID-19 vaccine rollout

Source: WHO Africa

Africa’s largest-ever vaccination drive is well underway.52 African countries are rolling out COVID-19 vaccines and over 73 million doses have been administered on the continent. With WHO support, Botswana is...

afro.who.int

WHO support to countries rolling out multiple COVID-19 vaccines

Source: WHO Africa

With 620 million COVID-19 vaccine doses set to arrive in Africa through COVAX alone by the end of 2021, African countries are set to roll out a range of different...

afro.who.int

Togo vaccinates over 90% of health workers against COVID-19

Source: WHO Africa

When Togo launched its COVID-19 vaccination campaign on 10 March, health workers on the frontlines of the pandemic were identified among the priority groups. 33 090 health workers have received...

fullfact.org

Australian government hasn’t admitted vaccines are a dangerous poison

Source: Full Fact

WHAT WAS CLAIMED The Australian government has admitted Covid-19 vaccines are a poison. OUR VERDICT Under Western Australian legislation, vaccines (alongside medicines such as paracetamol) are classed as poisons. This...

fullfact.org

Vaccine deaths are not higher than Covid-19 deaths

Source: Full Fact

WHAT WAS CLAIMED: Official data shows twice as many people have died due to the Covid-19 vaccines in six months than people who have died of Covid-19 in 15 months....

fullfact.org

Yellow Card data isn’t proof of Covid-19 vaccine deaths

Source: Full Fact

WHAT WAS CLAIMED: There have been 1,517 deaths and 1,102,228 adverse reactions caused by the Covid-19 vaccines in the UK. OUR VERDICT: These figures relate to the Yellow Card reports....

snopes.com

Did CDC Say That COVID-19 Vaccines Are ‘Failing’?

Source: Snopes

Claim: During a press briefing, the Centers for Disease Control and Prevention said that COVID-19 vaccines were “failing” and that vaccinated individuals were considered “superspreaders.” Rating: False. The CDC did...

snopes.com

No, the mRNA Vaccines Do Not Contain Graphene Oxide

Source: Snopes

Claim: COVID-19 mRNA vaccines contain graphene oxide. Rating: False. Vaccines do not contain graphene oxide

jwatch.org

Testing CoronaVac, an Inactivated SARS-CoV-2 Vaccine, in Turkey and Chile

Source: NEJM

Report on peer review article The efficacy study was conducted primarily in young, healthy persons, raising questions about generalization (especially regarding older patients and those with underlying illnesses). The effectiveness...

health.go.ke

Kenya received a further 180,000 doses of AstraZeneca vaccine. Nairobi August 6.

Source: KMoH

Kenya received a further 180,000 doses of AstraZeneca vaccine on 6 August 2021 in a boost to ongoing vaccination efforts amid increased Covid-19 cases across the country. The latest consignment,...

jwatch.org

How Well Does COVID-19 Vaccination Protect Against the Delta Variant?

Source: NEJM

Report on peer review article These findings provide reassurance that the mRNA-based BNT162b2 (Pfizer-BioNTech) and the adenovirus-based ChAdOx1 (Oxford/AstraZeneca) vaccines both have very good effectiveness against the Delta variant (although...

ecdc.europa.eu

ECDC and EMA update on COVID-19

Source: EU CDC

Infections in vaccinated people do not mean that vaccines do not work Although the effectiveness of all COVID-19 vaccines authorised in the EU/EEA is very high, no vaccine is 100%...

thelancet.com

Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study

Source: Lancet

Peer review article Vaccine induced blood clotting (VITT) is specifically associated with adenovirus vector vaccines against COVID-19 and urgent work is needed to elucidate the trigger for this reaction, in...

thelancet.com

Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies

Source: Lancet

Peer review article Data suggests that antibody production after a first COVID-19 vaccination is delayed in older patients on specific immunosuppressive drugs, but that second or repeated exposure to SARS-CoV-2,...

thelancet.com

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Source: Lancet

Peer review article Mixing ChAdOx1 nCoV-19, (AstraZeneca) and an mRNA vaccine (NT162b2, (Pfizer–BioNTech) as the first and second dose appears to not affect the safety of vaccinations. The results from...

bmj.com

Why Cuba developed its own covid vaccine—and what happened next

Source: BMJ

Rather than negotiating with pharmaceutical giants or the Covax vaccine sharing initiative, Cuba bet everything on its prestigious biotech sector coming up with its own vaccine against Covid-19. And though...

bmj.com

Should covid vaccination be mandatory for health and care staff?

Source: BMJ

Opinion piece New English law will make vaccination a condition of employment for eligible care home workers, following similar moves in Italy, France, and Greece for healthcare staff. This is...

bmj.com

Covid-19: WHO calls for booster shot ban until end of September

Source: BMJ

The World Health Organization has called for a moratorium on Covid-19 booster shots until the end of September to help vaccines reach poorer nations facing shortages. Wealthier countries with widespread...

cdc.gov

COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021

Source: US CDC

Report on pre-release peer-review article. Mild local and systemic reactions are common among adolescents following Pfizer-BioNTech vaccine, and serious adverse events are rare. The Advisory Committee on Immunization Practices conducted...

cdc.gov

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — COVID-NET, 13 States, February–April 2021

Source: US CDC

Report on pre-release peer-review article. Among adults aged 65–74 years, the effectiveness of full vaccination for preventing hospitalization was 96% for Pfizer-BioNTech, 96% for Moderna, and 84% for Janssen COVID-19...

cdc.gov

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021

Source: US CDC

Report on pre-release peer-review article. Among people infected with SARS-CoV-2 in 2020, the vaccination status of those reinfected during May–June 2021 was compared with that of residents who were not...

africacdc.org

Africa announces deployment of 400 million doses of vaccine in African Union and Caribbean member states

Source: Africa CDC

On August 5, the first monthly shipments will arrive through the African Vaccine Acquisition Fund (AVAT), in several member states and will continue to reach a total of 6.4 million...

who.int

COVID-19 vaccines available for all healthcare workers in the Western Pacific Region

Source: WHO

All countries and areas of the World Health Organization (WHO) Western Pacific Region have now secured sufficient doses of coronavirus disease 2019 (COVID-19) vaccine to protect all of their healthcare...

africacdc.org

African Vaccine Acquisition Trust (AVAT) announces 108,000 doses of vaccines arriving in Mauritius as part of the first monthly shipment of Johnson & Johnson vaccines

Source: Africa CDC

AVAT is pleased to announce the shipment of 108,000 of the Johnson & Johnson single-shot vaccines (JNJ-78436735/Ad26.COV2.S) to Mauritius on the 7th of August. This is part of a total...

afro.who.int

Sierra Leone welcomes the arrival of Covid-19 vaccines shipped via COVAX facility

Source: WHO Africa

Sierra Leone has today received the second batch of 96,000 doses of the AstraZeneca-Oxford COVID-19 vaccine donated by France and delivered by UNICEF through the COVAX Facility, a partnership between...

afro.who.int

A frontline health worker in Ethiopia shares her journey of caring for COVID-19 patients: How the COVID-19 vaccine encouraged her to do more with less fea

Source: WHO Africa

This is a story of a caseworker. Asmera confirms that although the work put her at high risk of contracting the disease, she was still very happy to be part...

poynter.org

A Facebook post showing a photo of Mike Tyson with an anti-vaccine T-shirt is fake

Source: Poynter

A similarly altered Tyson photo was used once before in connection with COVID-19 misinformation. On April 29, 2021, Full Fact debunked a claim that Tyson was wearing a shirt with...

poynter.org

Fact checks of 10 prominent types of misinformation about COVID-19 vaccines

Source: Poynter

“The COVID-19 vaccines do not work.” FACT: They do. “The COVID-19 vaccines were not properly tested or developed.” FACT: They were “The COVID-19 vaccines are mandatory.” FACT: They aren’t. “The...

poynter.org

Social media post misrepresents preliminary data on miscarriages and COVID-19 vaccines

Source: Poynter

An Instagram post claims that a scientific paper found an 82% miscarriage rate among women who got an mRNA COVID-19 vaccine between 30 days and 20 weeks pregnant. The Instagram...

poynter.org

When will the COVID-19 vaccines get full FDA approval?

Source: Poynter

The FDA on July 16 formally accepted Pfizer and BioNTech’s application for approval of the vaccine for people age 16 and older Moderna said in June that it had started...

fullfact.org

Vaccinated people sometimes die of Covid-19—but very rarely

Source: Full Fact

WHAT WAS CLAIMED Public Health England (PHE) released a report revealing 62% of Covid-19 deaths are people who have been vaccinated. OUR VERDICT PHE’s report suggests 61% of Covid-19 deaths...

fullfact.org

Video in a car shares misinformation about Covid-19 vaccines

Source: Full Fact

WHAT WAS CLAIMED Covid-19 has never been isolated in a laboratory. It has never been proven to exist. OUR VERDICT Covid-19 is the disease caused by the SARS-CoV-2 virus. This...

fullfact.org

Adverse event reports after vaccines are not necessarily due to vaccines

Source: Full Fact

WHAT WAS CLAIMED In the USA there have been 387,087 reports of adverse events after the Covid-19 vaccination. OUR VERDICT Adverse event reports after vaccination are not proof that the...

fullfact.org

The Pfizer vaccine isn’t 99% graphene oxide

Source: Full Fact

WHAT WAS CLAIMED The Pfizer vaccine is 99% graphene oxide. OUR VERDICT False. The MHRA has told Full Fact that this is ‘completely incorrect’.

fullfact.org

Free paper repeats falsehoods on deaths following vaccination

Source: Full Fact

WHAT WAS CLAIMED There have been 1,400 deaths and one million injured from Covid-19 vaccinations in the UK. OUR VERDICT These are deaths and potential side effects reported following the...

fullfact.org

Vaccines have not caused daily cases to increase

Source: Full Fact

WHAT WAS CLAIMED The vaccine is causing new daily cases of Covid-19 in the UK, or at least isn’t stopping them. OUR VERDICT Real world evidence and data from trials...

fullfact.org

Vaccines reduce the risk of death but don’t eliminate it altogether

Source: Full Fact

WHAT WAS CLAIMED Unvaccinated people are not dying from Covid-19. OUR VERDICT This is untrue, unvaccinated people are dying from Covid-19.

africacheck.org

No, Covid vaccines cannot make you magnetic as videos claim

Source: Africa check

This claim has been widely debunked. Some fact-checking organisations have also made the point that even if the vaccines did contain magnetic metals, one dose could not possibly cause a...

snopes.com

Mike Tyson’s Anti-Vaccine Shirt Photo Is Fake

Source: Snopes

Claim: A photograph shows former boxer Mike Tyson wearing a shirt that says "I believe in God, not in vaccines." Rating: False This isn’t the first time that a photograph...

africacheck.org

No, AstraZeneca vaccine not made year before Covid-19 emerged

Source: Africa check

The image appears to be a screenshot of a Facebook post with a Polish caption, which shows the packaging of an AstraZeneca Covid-19 vaccine. A pink arrow points to the...

snopes.com

No, 5 JetBlue Pilots Didn’t Die From the COVID-19 Vaccine

Source: Snopes

Claim: Five JetBlue pilots died as the result of receiving the COVID-19 vaccine. Rating: False This claim “False” because it comes from an unreliable source with a track record for...

snopes.com

Was COVID Vaccine Microchip Detected With Pet Scanner?

Source: Snopes

Claim: A viral video shows a pet scanner detecting a microchip from the COVID-19 vaccine in a person's arm. Rating: False While this TikTok user may have meant this short...

snopes.com

No, There Weren’t More COVID-19 Vaccine Deaths Than COVID-19 Deaths

Source: Snopes

Claim: There have been more deaths from COVID-19 vaccines than deaths from the actual virus. Rating: False Junk news site Gateway Pundit published a misleading story with a headline falsely...

snopes.com

Did 45K People Die Within 3 Days of Getting COVID Vaccine?

Source: Snopes

Claim: Some 45,000 Americans died within three days of receiving their COVID-19 vaccine. Rating: False Despite claiming to have evidence to prove that 45,000 individuals died within three days of...

nejm.org

Scaling Up Covid-19 Vaccination in Africa — Lessons from the HIV Pandemic

Source: NEJM

Opinion piece Each country will have its own unique challenges in vaccine distribution, which should be addressed with careful planning, including leveraging computational models of prioritization and rollout strategies, and...

nejm.org

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

Source: NEJM

Peer review article Results suggest that the inactivated SARS-CoV-2 vaccine (using a “dead” form of the virus) effectively prevented Covid-19, including severe disease and death, a finding that is consistent...

nejm.org

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Source: NEJM

Peer review article Only modest differences in vaccine effectiveness were noted with the delta variant as compared with the alpha variant after the receipt of two vaccine doses. Absolute differences...

nejm.org

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Source: NEJM

Peer review article Authorized mRNA vaccines were highly effective among working-age adults in preventing SARS-CoV-2 infection when administered in real-world conditions, and the vaccines reduced the viral RNA load, risk...

nejm.org

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Source: NEJM

Peer review article Among fully vaccinated health care workers, the occurrence of breakthrough infections, variants able to infect vaccinated people, with SARS-CoV-2 was correlated with antibodies detected in blood samples...

ecdc.europa.eu

Partial COVID-19 vaccination, vaccination following SARS-CoV-2 infection and heterologous vaccination schedule: summary of evidence

Source: EU CDC

This document provides a review of evidence on three topics of interest (effectiveness of partial vaccination, immunogenicity and effectiveness of vaccination for previously infected individuals and safety and immunogenicity of...

thelancet.com

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers

Source: Lancet

Peer review article BNT162b2 (Pfizer-BioNTech) vaccine induces a robust and rapid antibody response. The significant correlation between receptor-binding domain IgG antibodies and neutralisation titres suggests that IgG antibodies might serve...

thelancet.com

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Source: Lancet

Peer review article CoronaVac (Sinovac Biotech) has high efficacy (83.5%) against PCR-confirmed symptomatic COVID-19 with a good safety and tolerability profile.

thelancet.com

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

Source: Lancet

Peer review article Aerosolised Ad5-nCoV vaccine (CanSino Biologics) is well tolerated, and two doses of aerosolised Ad5-nCoV elicited neutralising antibody responses, similar to one dose of intramuscular injection. An aerosolised...

bmj.com

Covid-19: Millions could be offered booster vaccinations from September

Source: BMJ

COVID-19 booster vaccinations should be offered in England from September 2021, the Joint Committee on Vaccination and Immunisation has advised. But some experts have questioned the necessity and the practicalities...

bmj.com

Covid-19: Vaccines journal retracts controversial paper after editorial board members quit

Source: BMJ

A research paper that was promoted by anti-vaccination activists has been retracted by the journal Vaccines after several members of its editorial board resigned. Retracted: The Safety of COVID-19 Vaccinations-We...

bmj.com

Covid-19: China’s CoronaVac vaccine offers 83.5% protection against symptomatic infection, interim analysis finds

Source: BMJ

Two doses of the new CoronaVac vaccine made in China have an efficacy of 83.5% against symptomatic Covid-19, an interim analysis has shown. The vaccine, developed by the Chinese company...

bmj.com

Covid-19: Countries dump vaccines as demand slumps and sharing proves difficult

Source: BMJ

The US, the UK, and the Netherlands face throwing away tens of thousands of covid-19 vaccine doses that are due to expire. Over 3.5 billion vaccines have been distributed globally,...

bmj.com

Covid-19: Pfizer vaccine’s efficacy declined from 96% to 84% four months after second dose, company reports

Source: BMJ

The Pfizer-BioNTech vaccine’s efficacy against SARS-CoV-2 peaked at 96.2% at seven days to two months after the second dose and then declined to 83.7% at four months, a preprint from...

cdc.gov

COVID-19 Science Update released: July 2, 2021 Edition 96

Source: US CDC

Report on 5 peer review articles Prevention efforts need to focus on highly impacted older age groups and also on Hispanic/Latino, non-Hispanic Black, non-Hispanic AI/AN, and non-Hispanic populations, where a...

cdc.gov

COVID-19 Science Update released: July 9, 2021 Edition 97

Source: US CDC

Report on 8 peer review articles It is unknown how neutralising antibody production correlates with protection from infection. BNT162b2 (Pfizer-BioNTech) has been found to prevent symptomatic COVID-19 in persons ≥80...

cdc.gov

CDC Recommends Use of Johnson & Johnson’s Janssen COVID-19 Vaccine Resume

Source: US CDC

CDC and the U.S. Food and Drug Administration (FDA) recommend use of Johnson & Johnson’s Janssen (J&J/Janssen) COVID-19 Vaccine resume in the United States, after a temporary pause.

cdc.gov

COVID-19 Science Update released: July 16, 2021 Edition 98

Source: US CDC

Report on 4 peer review articles Coincident with rising prevalence and transmission of the SARS-CoV-2 Delta variant, positive cases continue to increase in England, with younger populations experiencing the largest...

cdc.gov

COVID-19 Science Update released: July 23, 2021 Edition 99

Source: US CDC

Report on 7 peer review articles The Black/White COVID-19 mortality ratio (in the US) has been declining and the driving force for the observed mortality convergence appears to be changes...

cdc.gov

COVID-19 Science Update released: July 30, 2021 Edition 100

Source: US CDC

Report on 5 peer review articles Peer review Transplant patients on specific therapies may not be protected following 2 SARS-CoV-2 mRNA vaccine doses. These individuals should continue to follow current...

who.int

Joint Statement of the Multilateral Leaders Task Force on COVID-19 Vaccines, Therapeutics, and Diagnostics for Developing Countries following its Second Meeting

Source: WHO

There is concern that vaccine delivery schedules and contracts for COVAX, AVAT, and low and low-middle income countries are delayed or too slow. Less than 5% of vaccine doses that...

africacdc.org

Statement on the remarkable progress made by several African countries as part of the Partnerships for African Vaccine Manufacturing (PAVM)

Source: Africa CDC

Strong political commitments were made to drive momentum for the African Union’s bold vision to manufacture about 60% of its vaccines on the continent by 2040, an initiative that will...

who.int

WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations

Source: WHO

WHO today validated the Sinovac-CoronaVac COVID-19 vaccine for emergency use, giving countries, funders, procuring agencies and communities the assurance that it meets international standards for safety, efficacy and manufacturing. The...

who.int

Updated WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines in the context of limited supply

Source: WHO

This interim guidance was initially issued in October 2020, based on advice from the Strategic Advisory Group of Experts (SAGE) on Immunization; it has been updated following the discussions at...

who.int

Statement on the eighth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic

Source: WHO

The Secretariat highlighted factors driving the current situation including: variants of concern, inconsistent application of public health and social measures, increased social mobility, and highly susceptible populations due to lack...

who.int

New consortium working to boost vaccine production in South Africa

Source: WHO

The Medicines Patent Pool (MPP) and the World Health Organization (WHO), Afrigen Biologics (PTY) Limited, the Biologicals and Vaccines Institute of Southern Africa (Biovac), the South African Medical Research Council...

who.int

Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™)

Source: WHO

These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory...

afro.who.int

Africa’s COVID-19 surge tops second wave peak as vaccine deliveries pick up

Source: WHO Africa

Africa marked its worst pandemic week ever, surpassing the second wave peak during the seven days ending on 4 July 2021. Yet, as the COVID-19 cases climb sharply, there are...

afro.who.int

Arrival of Johnson and Johnson Vaccines in The Gambia

Source: WHO Africa

One hundred and fifty-one thousand, two hundred (151,200) doses of the Johnson and Jonson (J&J) vaccine arrived in Gambia under the COVAX facility on 20 July.

afro.who.int

Inside Angola’s ‘exemplary’ COVID-19 vaccination hubs

Source: WHO Africa

“Good preparation, including around staffing and training needs, cold-chain logistics and getting the regulations right, were just some of the reasons why Angola was one of Africa’s first countries to...

afro.who.int

COVID-19 vaccine shipments to Africa ramp up

Source: WHO Africa

COVID-19 vaccine shipments to Africa are rapidly ramping up from multiple sources after a near-halt to deliveries in recent months. Nearly 4 million doses from COVAX arrived in Africa last...

afro.who.int

Leveraging lessons from Africa’s COVID-19 vaccine rollout

Source: WHO Africa

The beneficial lessons identified so far are categorized into four areas. They are early planning, delivering vaccines across the life-course, digital platforms and risk communications strategies. Key early challenges include...

Snopes

Was COVID Vaccine Microchip Detected With Pet Scanner?

Source: 7/2/21

Claim: A viral video shows a pet scanner detecting a microchip from the COVID-19 vaccine in a person's arm. Rating: False While this TikTok user may have meant this short...

NEJM

Scaling Up Covid-19 Vaccination in Africa — Lessons from the HIV Pandemic

Source: 7/15/21

Opinion piece Each country will have its own unique challenges in vaccine distribution, which should be addressed with careful planning, including leveraging computational models of prioritization and rollout strategies, and...

NEJM

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

Source: 7/7/21

Peer review article Results suggest that the inactivated SARS-CoV-2 vaccine (using a “dead” form of the virus) effectively prevented Covid-19, including severe disease and death, a finding that is consistent...

NEJM

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Source: 7/21/21

Peer review article Only modest differences in vaccine effectiveness were noted with the delta variant as compared with the alpha variant after the receipt of two vaccine doses. Absolute differences...

NEJM

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Source: 7/22/21

Peer review article Authorized mRNA vaccines were highly effective among working-age adults in preventing SARS-CoV-2 infection when administered in real-world conditions, and the vaccines reduced the viral RNA load, risk...

NEJM

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Source: 7/28/21

Peer review article Among fully vaccinated health care workers, the occurrence of breakthrough infections, variants able to infect vaccinated people, with SARS-CoV-2 was correlated with antibodies detected in blood samples...

EU CDC

Partial COVID-19 vaccination, vaccination following SARS-CoV-2 infection and heterologous vaccination schedule: summary of evidence

Source: 7/22/21

This document provides a review of evidence on three topics of interest (effectiveness of partial vaccination, immunogenicity and effectiveness of vaccination for previously infected individuals and safety and immunogenicity of...

Lancet

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers

Source: 7/2/21

Peer review article BNT162b2 (Pfizer-BioNTech) vaccine induces a robust and rapid antibody response. The significant correlation between receptor-binding domain IgG antibodies and neutralisation titres suggests that IgG antibodies might serve...

Lancet

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Source: 7/8/21

Peer review article CoronaVac (Sinovac Biotech) has high efficacy (83.5%) against PCR-confirmed symptomatic COVID-19 with a good safety and tolerability profile.

Lancet

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

Source: 7/26/21

Peer review article Aerosolised Ad5-nCoV vaccine (CanSino Biologics) is well tolerated, and two doses of aerosolised Ad5-nCoV elicited neutralising antibody responses, similar to one dose of intramuscular injection. An aerosolised...

BMJ

Covid-19: Millions could be offered booster vaccinations from September

Source: 7/2/21

COVID-19 booster vaccinations should be offered in England from September 2021, the Joint Committee on Vaccination and Immunisation has advised. But some experts have questioned the necessity and the practicalities...

BMJ

Covid-19: China’s CoronaVac vaccine offers 83.5% protection against symptomatic infection, interim analysis finds

Source: 7/9/21

Two doses of the new CoronaVac vaccine made in China have an efficacy of 83.5% against symptomatic Covid-19, an interim analysis has shown. The vaccine, developed by the Chinese company...

BMJ

Covid-19: Countries dump vaccines as demand slumps and sharing proves difficult

Source: 7/27/21

The US, the UK, and the Netherlands face throwing away tens of thousands of covid-19 vaccine doses that are due to expire. Over 3.5 billion vaccines have been distributed globally,...

BMJ

Covid-19: Pfizer vaccine’s efficacy declined from 96% to 84% four months after second dose, company reports

Source: 7/30/21

The Pfizer-BioNTech vaccine’s efficacy against SARS-CoV-2 peaked at 96.2% at seven days to two months after the second dose and then declined to 83.7% at four months, a preprint from...

US CDC

COVID-19 Science Update released: July 2, 2021 Edition 96

Source: 7/2/21

Report on 5 peer review articles Prevention efforts need to focus on highly impacted older age groups and also on Hispanic/Latino, non-Hispanic Black, non-Hispanic AI/AN, and non-Hispanic populations, where a...

US CDC

COVID-19 Science Update released: July 9, 2021 Edition 97

Source: 7/9/21

Report on 8 peer review articles It is unknown how neutralising antibody production correlates with protection from infection. BNT162b2 (Pfizer-BioNTech) has been found to prevent symptomatic COVID-19 in persons ≥80...

US CDC

COVID-19 Science Update released: July 16, 2021 Edition 98

Source: 7/16/21

Report on 4 peer review articles Coincident with rising prevalence and transmission of the SARS-CoV-2 Delta variant, positive cases continue to increase in England, with younger populations experiencing the largest...

US CDC

CDC Recommends Use of Johnson & Johnson’s Janssen COVID-19 Vaccine Resume

Source: 7/13/21

CDC and the U.S. Food and Drug Administration (FDA) recommend use of Johnson & Johnson’s Janssen (J&J/Janssen) COVID-19 Vaccine resume in the United States, after a temporary pause.

US CDC

COVID-19 Science Update released: July 23, 2021 Edition 99

Source: 7/23/21

Report on 7 peer review articles The Black/White COVID-19 mortality ratio (in the US) has been declining and the driving force for the observed mortality convergence appears to be changes...

US CDC

COVID-19 Science Update released: July 30, 2021 Edition 100

Source: 7/30/21

Report on 5 peer review articles Peer review Transplant patients on specific therapies may not be protected following 2 SARS-CoV-2 mRNA vaccine doses. These individuals should continue to follow current...

Africa

Statement on the remarkable progress made by several African countries as part of the Partnerships for African Vaccine Manufacturing (PAVM)

Source: 7/13/21

Strong political commitments were made to drive momentum for the African Union’s bold vision to manufacture about 60% of its vaccines on the continent by 2040, an initiative that will...

WHO

Joint Statement of the Multilateral Leaders Task Force on COVID-19 Vaccines, Therapeutics, and Diagnostics for Developing Countries following its Second Meeting

Source: 7/30/21

There is concern that vaccine delivery schedules and contracts for COVAX, AVAT, and low and low-middle income countries are delayed or too slow. Less than 5% of vaccine doses that...

WHO

WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations

Source: 7/1/21

WHO today validated the Sinovac-CoronaVac COVID-19 vaccine for emergency use, giving countries, funders, procuring agencies and communities the assurance that it meets international standards for safety, efficacy and manufacturing. The...

WHO

Statement on the eighth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic

Source: 7/15/21

The Secretariat highlighted factors driving the current situation including: variants of concern, inconsistent application of public health and social measures, increased social mobility, and highly susceptible populations due to lack...

WHO

Updated WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines in the context of limited supply

Source: 7/16/21

This interim guidance was initially issued in October 2020, based on advice from the Strategic Advisory Group of Experts (SAGE) on Immunization; it has been updated following the discussions at...

WHO

Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™)

Source: 7/30/21

These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory...

WHO

New consortium working to boost vaccine production in South Africa

Source: 7/30/21

The Medicines Patent Pool (MPP) and the World Health Organization (WHO), Afrigen Biologics (PTY) Limited, the Biologicals and Vaccines Institute of Southern Africa (Biovac), the South African Medical Research Council...

WHO Africa

Africa’s COVID-19 surge tops second wave peak as vaccine deliveries pick up

Source: 7/8/21

Africa marked its worst pandemic week ever, surpassing the second wave peak during the seven days ending on 4 July 2021. Yet, as the COVID-19 cases climb sharply, there are...

WHO Africa

COVID-19 vaccine shipments to Africa ramp up

Source: 7/29/21

COVID-19 vaccine shipments to Africa are rapidly ramping up from multiple sources after a near-halt to deliveries in recent months. Nearly 4 million doses from COVAX arrived in Africa last...

WHO Africa

Arrival of Johnson and Johnson Vaccines in The Gambia

Source: 7/24/21

One hundred and fifty-one thousand, two hundred (151,200) doses of the Johnson and Jonson (J&J) vaccine arrived in Gambia under the COVAX facility on 20 July.

WHO Africa

Leveraging lessons from Africa’s COVID-19 vaccine rollout

Source: 7/3/21

The beneficial lessons identified so far are categorized into four areas. They are early planning, delivering vaccines across the life-course, digital platforms and risk communications strategies. Key early challenges include...

WHO Africa

Inside Angola’s ‘exemplary’ COVID-19 vaccination hubs

Source: 7/2/21

“Good preparation, including around staffing and training needs, cold-chain logistics and getting the regulations right, were just some of the reasons why Angola was one of Africa’s first countries to...

KMoH

Kenya received a further 180,000 doses of AstraZeneca vaccine. Nairobi August 6.

Source: 8/6/21

Kenya received a further 180,000 doses of AstraZeneca vaccine on 6 August 2021 in a boost to ongoing vaccination efforts amid increased Covid-19 cases across the country. The latest consignment,...

NEJM

Testing CoronaVac, an Inactivated SARS-CoV-2 Vaccine, in Turkey and Chile

Source: 8/3/21

Report on peer review article The efficacy study was conducted primarily in young, healthy persons, raising questions about generalization (especially regarding older patients and those with underlying illnesses). The effectiveness...

NEJM

How Well Does COVID-19 Vaccination Protect Against the Delta Variant?

Source: 9/4/21

Report on peer review article These findings provide reassurance that the mRNA-based BNT162b2 (Pfizer-BioNTech) and the adenovirus-based ChAdOx1 (Oxford/AstraZeneca) vaccines both have very good effectiveness against the Delta variant (although...

EU CDC

ECDC and EMA update on COVID-19

Source: 8/4/21

Infections in vaccinated people do not mean that vaccines do not work Although the effectiveness of all COVID-19 vaccines authorised in the EU/EEA is very high, no vaccine is 100%...

Lancet

Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies

Source: 8/6/21

Peer review article Data suggests that antibody production after a first COVID-19 vaccination is delayed in older patients on specific immunosuppressive drugs, but that second or repeated exposure to SARS-CoV-2,...

Lancet

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Source: 8/6/21

Peer review article Mixing ChAdOx1 nCoV-19, (AstraZeneca) and an mRNA vaccine (NT162b2, (Pfizer–BioNTech) as the first and second dose appears to not affect the safety of vaccinations. The results from...

Lancet

Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study

Source: 8/6/21

Peer review article Vaccine induced blood clotting (VITT) is specifically associated with adenovirus vector vaccines against COVID-19 and urgent work is needed to elucidate the trigger for this reaction, in...

BMJ

Why Cuba developed its own covid vaccine—and what happened next

Source: 8/5/21

Rather than negotiating with pharmaceutical giants or the Covax vaccine sharing initiative, Cuba bet everything on its prestigious biotech sector coming up with its own vaccine against Covid-19. And though...

BMJ

Should covid vaccination be mandatory for health and care staff?

Source: 8/5/21

Opinion piece New English law will make vaccination a condition of employment for eligible care home workers, following similar moves in Italy, France, and Greece for healthcare staff. This is...

BMJ

Covid-19: WHO calls for booster shot ban until end of September

Source: 8/5/21

The World Health Organization has called for a moratorium on Covid-19 booster shots until the end of September to help vaccines reach poorer nations facing shortages. Wealthier countries with widespread...

US CDC

COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021

Source: 8/6/21

Report on pre-release peer-review article. Mild local and systemic reactions are common among adolescents following Pfizer-BioNTech vaccine, and serious adverse events are rare. The Advisory Committee on Immunization Practices conducted...

US CDC

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021

Source: 8/6/21

Report on pre-release peer-review article. Among people infected with SARS-CoV-2 in 2020, the vaccination status of those reinfected during May–June 2021 was compared with that of residents who were not...

Africa CDC

Africa announces deployment of 400 million doses of vaccine in African Union and Caribbean member states

Source: 8/5/21

On August 5, the first monthly shipments will arrive through the African Vaccine Acquisition Fund (AVAT), in several member states and will continue to reach a total of 6.4 million...

US CDC

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — COVID-NET, 13 States, February–April 2021

Source: 8/6/21

Report on pre-release peer-review article. Among adults aged 65–74 years, the effectiveness of full vaccination for preventing hospitalization was 96% for Pfizer-BioNTech, 96% for Moderna, and 84% for Janssen COVID-19...

WHO

COVID-19 vaccines available for all healthcare workers in the Western Pacific Region

Source: 8/6/21

All countries and areas of the World Health Organization (WHO) Western Pacific Region have now secured sufficient doses of coronavirus disease 2019 (COVID-19) vaccine to protect all of their healthcare...

Africa CDC

African Vaccine Acquisition Trust (AVAT) announces 108,000 doses of vaccines arriving in Mauritius as part of the first monthly shipment of Johnson & Johnson vaccines

Source: 8/7/21

AVAT is pleased to announce the shipment of 108,000 of the Johnson & Johnson single-shot vaccines (JNJ-78436735/Ad26.COV2.S) to Mauritius on the 7th of August. This is part of a total...

WHO Africa

Sierra Leone welcomes the arrival of Covid-19 vaccines shipped via COVAX facility

Source: 8/8/21

Sierra Leone has today received the second batch of 96,000 doses of the AstraZeneca-Oxford COVID-19 vaccine donated by France and delivered by UNICEF through the COVAX Facility, a partnership between...

WHO Africa

A frontline health worker in Ethiopia shares her journey of caring for COVID-19 patients: How the COVID-19 vaccine encouraged her to do more with less fea

Source: 5/9/21

This is a story of a caseworker. Asmera confirms that although the work put her at high risk of contracting the disease, she was still very happy to be part...

poynter.org

The WHO did not reverse its position on kids getting COVID-19 vaccines

Source: Poynter

A social media post on Instagram claims that the World Health Organization recently flipped its policy recommendation about children receiving a COVID-19 vaccine. This is based on the misinterpretation of...

fullfact.org

Vaccinated people are not warned against flying

Source: Fullfact

Claim: Airlines in Spain and Russia have warned people vaccinated against Covid-19 not to fly. Verdict; This is not true.

snopes.com

No, Four British Airways Pilots Did Not Die From COVID-19 Vaccine

Source: Snopes

Claim: In the summer of 2021, COVID-19 vaccination killed four British Airways pilots. Rating: False.

snopes.com

Nearly 4K COVID-19 Patients in Massachusetts Had Been Vaccinated. Here’s the Full Story.

Source: Snopes

Claim: Nearly 4,000 fully vaccinated people in Massachusetts tested positive for COVID-19. Rating: True. The CDC stated in the past that such breakthrough cases (where the vaccine does not provide...

nejm.org

Effect of Vaccination on Household Transmission of SARS-CoV-2 in England

Source: NEJM

People who had been vaccinated were likely to be less severely symptomatic and might have been less infectious than those who were unvaccinated.

nejm.org

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Source: NEJM

This study showed that administration of a third dose of the Pfizer-BioNTech vaccine to solid-organ transplant recipients significantly improved the immunogenicity of the vaccine, with no cases of Covid-19 reported...

nejm.org

SARS-CoV-2 Variants and Vaccines

Source: NEJM

Viral variants of concern may emerge with dangerous resistance to the immunity generated by the current vaccines to prevent coronavirus disease 2019 (Covid-19).

thelancet.com

Global COVID-19 vaccine inequity

Source: Lancet

The Serum Institute of India has suspended exports of the vaccine in order to combat the huge surge in domestic cases of COVID-19. The quickest way to achieve greater output...

thelancet.com

Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study

Source: Lancet

One dose of either Pfizer or AstraZeneca resulted in substantial risk reductions of COVID-19-related hospitalisation in people aged at least 80 years.

thelancet.com

Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study

Source: Lancet

Single-dose vaccination with Pfizer and AstraZeneca vaccines provide substantial protection against infection in older adults from 4–7 weeks after vaccination and might reduce SARS-CoV-2 transmission.

thelancet.com

India’s COVID-19 response: science first

Source: Lancet

Critique of the article published (26/06/2021): It is sad to see that the Editors are keen to give a verdict on the Indian COVID-19 emergency and the so-called botched vaccination...

thelancet.com

What constitutes success in the roll-out of COVID-19 vaccines?

Source: Lancet

The public is acutely aware of how their country, state, or province stacks up relative to others. Countries should also be evaluated on metrics that correspond to the actual public...

thelancet.com

Heterologous vaccine regimens against COVID-19

Source: Lancet

Heterologous vaccination regimens against COVID-19 provide an opportunity to speed up vaccination campaigns worldwide, maximising their impact on the control of the pandemic.

thelancet.com

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Source: Lancet

Pfizer given as a second dose in individuals prime vaccinated with AstraZeneca induced a robust immune response, with an acceptable and manageable profile of COVID-19 like symptoms.

bmj.com

Covid-19: Should we be worried about reports of myocarditis and pericarditis after mRNA vaccines?

Source: BMJ

The American Medical Association emphasised that the side effect was “extremely rare” and that most cases were mild.

bmj.com

Covid-19: US doctors suggest new ways to target vaccine hesitancy

Source: BMJ

Instead of vaccines being administered by age groups, as it was in the beginning, vaccine centres could allow family groups to be vaccinated together to promote a family orientated thought...

cdc.gov

COVID-19 Science Update released: June 25, 2021 Edition 95

Source: US CDC

Report on 6 peer review articles and 4 pre-release peer review articles

cdc.gov

COVID-19 Science Update released: June 18, 2021 Edition 94

Source: US CDC

Report on 7 peer review articles and 1 pre-release peer review articles

who.int

At Local Production Forum, WHO and partners highlight key steps to improve access to health technologies

Source: WHO

The COVID-19 pandemic has highlighted the importance of local manufacturing as a key component of pandemic response by reducing reliance on global markets and imported products.

who.int

WHO supporting South African consortium to establish first COVID mRNA vaccine technology transfer hub

Source: WHO

This landmark initiative is a major advance in the international effort to build vaccine development and manufacturing capacity that will put Africa on a path to self-determination

who.int

Directors General of WHO, WIPO and the WTO agree on intensified cooperation in support of access to medical technologies worldwide to tackle the COVID-19 pandemic

Source: WHO

A one-stop shop that will make available the full range of expertise on access, IP and trade matters provided by our organizations, and other partners, in a coordinated and systematic...

fullfact.org

There’s no evidence Covid-19 vaccines make the disease worse

Source: Full Fact

Antibody dependant enhancement is a rare but genuine risk when it comes to creating new vaccines. There is good evidence that this does not occur with the current COVID-19 vaccines...

fullfact.org

Possible link between Pfizer second dose and mild heart inflammation in young men

Source: Full Fact

Researchers reporting to the health ministry in Israel have found a possible link between mild myocarditis in young men and the second dose of the Pfizer COVID-19 vaccine.

nejm.org

Delayed Large Local Reactions to mRNA Covid-19 Vaccines in Blacks, Indigenous Persons, and People of Color

Source: NEJM

Opinion piece: Delayed large local reactions may be less commonly recognized or reported in non-white vaccine recipients than in white recipients.

nejm.org

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Source: NEJM

Vaccination against SARS-CoV-2 remains critical for control of the COVID-19 pandemic. Rapid identification of the rare syndrome of uncontrolled blood clot after administration of AstraZeneca is important because of the...

nejm.org

Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia

Source: NEJM

The use of high-dose intravenous immune globulin (IVIG) plus anticoagulation is recommended for the treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare side effect of adenoviral vector vaccines against...

thelancet.com

Should we vaccinate children against SARS-CoV-2?

Source: Lancet

Whether at present the children of high-income countries should be prioritised for vaccination over vulnerable adults in low and middle-income countries is a matter for serious ethical and practical debate.

thelancet.com

COVID-19 vaccine efficacy data: solid enough to delay second dose? – Authors’ reply

Source: Lancet

Reported adjusted rate reductions of 75% on all SARS-CoV-2 infections and 85% in symptomatic COVID-19 during days 15–28 after the first dose of Pfizer.

thelancet.com

ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates

Source: Lancet

Opinion piece: Estimate efficacy against asymptomatic COVID-19 cases to be 61·9% which is much higher than the reported estimate of 22·2%.

thelancet.com

SARS-CoV-2 vaccination for patients with inflammatory bowel disease

Source: Lancet

Opinion piece: mRNA vaccines might prove to be the better option for patients with IBD using immunosuppressants than adenovirus vector vaccines for two reasons

bmj.com

Covid-19: AstraZeneca vaccine linked with small risk of ITP, real world data show

Source: BMJ

The autoimmune bleeding disorder is characterised by a decrease in the number of platelets, which can cause minor bruising in some patients and excessive bleeding and long term illness in...

cdc.gov

COVID-19 Science Update released: June 11, 2021 Edition 93

Source: US CDC

Report on 6 peer review articles and 4 pre-release peer review articles.

africacdc.org

Africa CDC, Mastercard Foundation Partnership Announcement

Source: WHO

This partnership for COVID-19 vaccination will support Member States in fighting the COVID-19 pandemic through large-scale vaccination with safe and efficacious vaccines against the disease.

africacdc.org

Mastercard Foundation to deploy $1.3 billion in partnership with Africa CDC to save lives and livelihoods

Source: WHO

The funds will be used to save the lives and livelihoods of millions of people in Africa and hasten the economic recovery of the continent.

who.int

Statement for healthcare professionals: How COVID-19 vaccines are regulated for safety and effectiveness

Source: WHO

Emerging data on effectiveness indicates that licenced COVID-19 vaccines are contributing to controlling the spread of the disease. Vaccines are monitored on many levels including efficacy, quality and safety. There...

afro.who.int

Nine in 10 African countries set to miss urgent COVID-19 vaccination goal

Source: WHO Africa

The new global targets were announced recently at the World Health Assembly, and at today’s pace, only seven African countries are set to meet them.

afro.who.int

Over 1 million doses of COVID-19 vaccine administered in Angola

Source: WHO Africa

Angola has reached the milestone of more than 1 million doses of COVID-19 vaccines administered after receiving the first doses from COVAX.

afro.who.int

Tackling surges in severe COVID-19 cases in Africa

Source: WHO Africa

Africa has the highest global mortality rate among critically ill COVID-19 patients despite having the world’s lowest COVID-19 infections and deaths overall, a recent study published by the Lancet found.

afro.who.int

How Senegal prepared for COVID-19 surge

Source: WHO Africa

Actions include strengthening disease surveillance at all levels to swiftly detect cases for isolation and monitoring, and expanded vaccination as much as possible.

afro.who.int

What it means to be more vulnerable to COVID-19: Adwoa Afrakoma shares her story

Source: WHO Africa

A story of a 69-year-old from Kumasi in the Ashanti Region reflecting on how the vaccine affected her and her family.

fullfact.org

There’s no evidence Covid-19 vaccines make the disease worse

Source: Full Fact

Antibody dependant enhancement is a rare but genuine risk when it comes to creating new vaccines. There is good evidence that this does not occur with the current COVID-19 vaccines...

fullfact.org

Possible link between Pfizer second dose and mild heart inflammation in young men

Source: Full Fact

Researchers reporting to the health ministry in Israel have found a possible link between mild myocarditis in young men and the second dose of the Pfizer COVID-19 vaccine.

nejm.org

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Source: NEJM

Vaccination against SARS-CoV-2 remains critical for control of the COVID-19 pandemic. Rapid identification of the rare syndrome of uncontrolled blood clot after administration of AstraZeneca is important because of the...

nejm.org

Delayed Large Local Reactions to mRNA Covid-19 Vaccines in Blacks, Indigenous Persons, and People of Color

Source: NEJM

Opinion piece: Delayed large local reactions may be less commonly recognized or reported in non-white vaccine recipients than in white recipients.

nejm.org

Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia

Source: NEJM

The use of high-dose intravenous immune globulin (IVIG) plus anticoagulation is recommended for the treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare side effect of adenoviral vector vaccines against...

thelancet.com

Should we vaccinate children against SARS-CoV-2?

Source: Lancet

Whether at present the children of high-income countries should be prioritised for vaccination over vulnerable adults in low and middle-income countries is a matter for serious ethical and practical debate.

thelancet.com

ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates

Source: Lancet

Opinion piece: Estimate efficacy against asymptomatic COVID-19 cases to be 61·9% which is much higher than the reported estimate of 22·2%.

thelancet.com

COVID-19 vaccine efficacy data: solid enough to delay second dose? – Authors’ reply

Source: Lancet

Reported adjusted rate reductions of 75% on all SARS-CoV-2 infections and 85% in symptomatic COVID-19 during days 15–28 after the first dose of Pfizer.

thelancet.com

SARS-CoV-2 vaccination for patients with inflammatory bowel disease

Source: Lancet

Opinion piece: mRNA vaccines might prove to be the better option for patients with IBD using immunosuppressants than adenovirus vector vaccines for two reasons

bmj.com

Covid-19: AstraZeneca vaccine linked with small risk of ITP, real world data show

Source: BMJ

The autoimmune bleeding disorder is characterised by a decrease in the number of platelets, which can cause minor bruising in some patients and excessive bleeding and long term illness in...

africacdc.org

Mastercard Foundation to deploy $1.3 billion in partnership with Africa CDC to save lives and livelihoods

Source: WHO

The funds will be used to save the lives and livelihoods of millions of people in Africa and hasten the economic recovery of the continent.

africacdc.org

Africa CDC, Mastercard Foundation Partnership Announcement

Source: WHO

This partnership for COVID-19 vaccination will support Member States in fighting the COVID-19 pandemic through large-scale vaccination with safe and efficacious vaccines against the disease.

cdc.gov

COVID-19 Science Update released: June 11, 2021 Edition 93

Source: US CDC

Report on 6 peer review articles and 4 pre-release peer review articles.

who.int

Statement for healthcare professionals: How COVID-19 vaccines are regulated for safety and effectiveness

Source: WHO

Emerging data on effectiveness indicates that licenced COVID-19 vaccines are contributing to controlling the spread of the disease. Vaccines are monitored on many levels including efficacy, quality and safety. There...

afro.who.int

Over 1 million doses of COVID-19 vaccine administered in Angola

Source: WHO Africa

Angola has reached the milestone of more than 1 million doses of COVID-19 vaccines administered after receiving the first doses from COVAX.

afro.who.int

Nine in 10 African countries set to miss urgent COVID-19 vaccination goal

Source: WHO Africa

The new global targets were announced recently at the World Health Assembly, and at today’s pace, only seven African countries are set to meet them.

afro.who.int

How Senegal prepared for COVID-19 surge

Source: WHO Africa

Actions include strengthening disease surveillance at all levels to swiftly detect cases for isolation and monitoring, and expanded vaccination as much as possible.

afro.who.int

Tackling surges in severe COVID-19 cases in Africa

Source: WHO Africa

Africa has the highest global mortality rate among critically ill COVID-19 patients despite having the world’s lowest COVID-19 infections and deaths overall, a recent study published by the Lancet found.

afro.who.int

What it means to be more vulnerable to COVID-19: Adwoa Afrakoma shares her story

Source: WHO Africa

A story of a 69-year-old from Kumasi in the Ashanti Region reflecting on how the vaccine affected her and her family.

thelancet.com

India faces a challenge with its mass vaccination efforts

Source: Lancet

Mass vaccination exercise in the middle of a pandemic has the potential to become a super-spreader event with reports of overcrowding in centres administering vaccines.

thelancet.com

Bhutan: small nation, big ideas affecting respiratory health

Source: Lancet

Bhutan started its COVID-19 vaccination rollout on March 27, 2021. In two weeks, it had reached more than 90% of the adult population eligible for vaccination.

blogs.bmj.com

Covid-19 in Nepal: a lack of preparedness and a lack of vaccines

Source:

South Asian policymakers need to seriously plan for universal healthcare and consider universal basic income, if they are going to improve healthcare for the vast majority of people in the...

fullfact.org

Having a Covid-19 vaccine doesn’t make you more vulnerable to the disease

Source: Full Fact

Claim: Covid-19 vaccines cause vaccine enhancement syndrome which makes you even more vulnerable to the disease. Verdict: This is not true.

cdc.gov

COVID-19 Science Update released: May 21, 2021 Edition 90

Source: US CDC

Report on 6 peer review articles and 3 pre-release peer review articles.

bmj.com

Vaccinating children against SARS-CoV-2

Source: BMJ

Opinion piece: Young people have been largely spared from severe COVID-19 so far and the value of childhood vaccination against respiratory viruses, in general, remains an open question.

thelancet.com

Why we vaccinate incarcerated people first

Source: The Lancet

Incarcerated individuals are at high risk for Covid-19 transmission and severe disease. Congregate living settings, including jails and prisons, facilitate the rapid spread of infection.

blogs.bmj.com

Amitava Banerjee: Covid-19 in India—lockdown and vaccination drive only way forward

Source: BMJ

Only reducing the infection rate with a full suppression strategy via stringent lockdown will act quickly within days to reduce the daily death toll.

bmj.com

Covid-19: Vaccines will be tested against variants of concern after £29m funding boost from UK government

Source: BMJ

The efficacy of different COVID-19 vaccines against variants of concern, including those first identified in the UK and South Africa, will be assessed by Public Health England after a funding...

bmj.com

Covid-19: Sputnik vaccine rockets, thanks to Lancet boost

Source: BMJ

A Lancet paper seems to have given other countries confidence before the publication of the phase III trial (demonstrating the safety and effectiveness) 16 countries had authorised Sputnik V for...

bmj.com

Covid-19: India’s crisis is everyone’s crisis

Source: BMJ

While SARS-CoV-2 can circulate freely in Brazil, India, and elsewhere, new variants may undermine any nation’s vaccination strategy.

blogs.bmj.com

Thrombosis and bleeding after the Oxford-AstraZeneca covid-19 vaccination

Source: BMJ

This study has been able to give a better understanding of how many people in the population have died from COVID-19, after AstraZeneca vaccine.

bmj.com

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

Source: BMJ

Peer review article Research into the ChAdOx1-S/AZD1222 (Oxford/AstraZeneca) vaccine show risks of venous thromboembolic (blood clotting) events were, however, small, and the findings should be interpreted in the light of...

cdc.gov

CDC Recommends Use of Johnson & Johnson’s Janssen COVID-19 Vaccine Resume

Source: US CDC

CDC and FDA recommend use of Johnson & Johnson’s Janssen COVID-19 Vaccine resume in the United States, after a temporary pause.

who.int

WHO lists Moderna vaccine for emergency use

Source: WHO

WHO listed the Moderna COVID-19 vaccine (mRNA 1273) for emergency use, making it the fifth vaccine to receive emergency validation from WHO.

who.int

WHO welcomes Sweden’s announcement to share COVID-19 vaccine doses with COVAX

Source: WHO

Sweden announced that they will share 1 million doses of the AstraZeneca vaccine with the COVAX Facility to provide vaccines to people at risk in low-income countries.

who.int

Expanding reach: Addressing gender barriers in COVID-19 vaccine rollout

Source: WHO

During the largest global vaccine deployment in history, COVID-19 vaccination rollout must reach women, men, and gender-diverse people quickly and efficiently.

who.int

WHO Director-General commends United States decision to support temporary waiver on intellectual property rights for COVID-19 vaccines

Source: WHO

WHO Director-General praised the commitment by the United States administration to end the pandemic as quickly as possible.

who.int

The Partnership for Healthy Cities supports COVID-19 Vaccine Outreach in 18 Cities

Source: WHO

Partnership cities in low- and middle-income countries were eligible to apply for this assistance and get grants of up to $50,000 to help promote or administer vaccinations.

who.int

WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations

Source: WHO

WHO today listed the Sinopharm COVID-19 vaccine for emergency use, giving the green light for this vaccine to be rolled out globally.

afro.who.int

Vaccine supply crunch adds to risk of COVID-19 resurgence

Source: WHO Africa

Africa’s vaccination coverage is the lowest for any region of the world. Low vaccination coverage places African countries at higher risk of a massive upsurge in cases.

fullfact.org

No evidence rapper DMX had Covid-19 vaccine before his death

Source: Full Fact

There’s no evidence DMX had a Covid-19 vaccine just before his heart attack and no evidence that Covid-19 vaccines cause heart attacks.

jwatch.org

Viral Load in Breakthrough Infection After Receiving the Pfizer-BioNTech COVID-19 Vaccine

Source: NEJM

The authors defined 12 days after the first vaccine dose as the time when protective immunity develops. They also indicate that immunization results in lower viral burden and lower risk...

jwatch.org

COVID-19 Vaccines: Facial Paralysis / CDC J&J Guidance

Source: NEJM

The COVID-19 mRNA vaccines do not appear to pose any higher risk for facial paralysis than other viral vaccines, according to an analysis in JAMA Internal Medicine.

jwatch.org

Vaccines Protect Against COVID-19–Related Hospitalization in Older Adults

Source: NEJM

These data suggest that continuing to rapidly vaccinate U.S. adults ... will likely have a marked impact on COVID-19 hospitalization and might lead to commensurate reductions in post-COVID conditions and...

nejm.org

Beyond the First Dose — Covid-19 Vaccine Follow-through and Continued Protective Measures

Source: NEJM

Vaccination campaigns must not only address concerns about product safety but must also provide clear guidance about vaccine benefits.

ecdc.europa.eu

EMA and ECDC join forces for enhanced post-marketing monitoring of COVID-19 vaccines in Europe

Source: EU CDC

The European Medical Agency and European Centre for Disease Control will jointly coordinate and oversee a number of observational studies which will be funded from the EU budget and conducted...

ecdc.europa.eu

Objectives of vaccination strategies against COVID-19

Source: EU CDC

This document provides an overview of the possible goals of vaccination against COVID-19 and reflects on potential implications.

thelancet.com

Symptom study app provides real-world data on COVID-19 vaccines

Source: The Lancet

This app is a community-led initiative designed to capture longitudinal data relating to the COVID-19 pandemic, with more than 4·5 million contributors.

thelancet.com

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study

Source: The Lancet

Systemic and local side-effects after Pfizer and AstraZeneca vaccination in the UK occur at frequencies lower than reported in phase 3 trials.

thelancet.com

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Source: The Lancet

In patients with cancer, one dose of the BNT162b2 (Pfizer-BioNTech) vaccine yields poor efficacy. Immunogenicity (the ability of a vaccine to provoke an immune response) increased significantly in patients with...

thelancet.com

COVID-19 vaccines: building and maintaining confidence

Source: The Lancet

There is clear evidence of the benefits of all the approved COVID-19 vaccines, including AstraZeneca, for preventing serious COVID-19 and helping nations control the disease.

bmj.com

Covid-19: US authorises Johnson and Johnson vaccine again, ending pause in rollout

Source: BMJ

FDA has concluded that the known and potential benefit of the . . . vaccine outweigh[s] its known and potential risks in individuals 18 years of age and older.

bmj.com

Covid-19: Most people admitted to hospital after vaccination were infected before immunity could develop, research shows

Source: BMJ

This highlightes the importance of maintaining social distancing and understanding that immunity develops over time, researchers have said

bmj.com

Covid-19: US will send 60 million AstraZeneca doses abroad as domestic demand falls

Source: BMJ

The Biden administration has announced that the US will send as many as 60 million doses of the AstraZeneca vaccine to countries in need.

bmj.com

Covid-19: One dose of vaccine cuts risk of passing on infection by as much as 50%, research shows

Source: BMJ

Adults infected with Covid-19 three weeks after receiving one dose of the Pfizer-BioNTech or Oxford-AstraZeneca vaccine were 38-49% less likely to pass the virus on to their household contacts than...

bmj.com

Covid-19: Booster vaccine to be rolled out in autumn as UK secures 60m more Pfizer doses

Source: BMJ

The UK will roll out a Covid-19 booster vaccine at the beginning of autumn in order to protect the most vulnerable ahead of winter.

cdc.gov

Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021

Source: US CDC

In a multistate network of U.S. hospitals during January March 2021, receipt of Pfizer-BioNTech or Moderna COVID-19 vaccines was 94% effective against COVID-19 hospitalization among fully vaccinated adults and 64%...

cdc.gov

Interim Public Health Recommendations for Fully Vaccinated People

Source: US CDC

A diagram showing which activities are more or less safe based on whether someone has been vaccinated or not.

cdc.gov

CDC Recommends Use of Johnson & Johnson’s Janssen COVID-19 Vaccine Resume

Source: US CDC

CDC and FDA recommend use of J&J COVID-19 vaccine in the United States after a temporary pause.

cdc.gov

Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination — Five U.S. Mass Vaccination Sites, April 2021

Source: US CDC

Vaccine providers should be aware of anxiety-related events after vaccination and observe all COVID-19 vaccine recipients for at least 15 minutes after administration.

cdc.gov

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021

Source: US CDC

A review of safety monitoring data found that 97% of reported reactions after the Jansen COVID-19 vaccine receipt were nonserious, consistent with preauthorization clinical trials data.

who.int

Immunization services begin slow recovery from COVID-19 disruptions, though millions of children remain at risk from deadly diseases – WHO, UNICEF, Gavi

Source: WHO

World Immunization Week highlighted the urgent need for a renewed global commitment to improving vaccination access and uptake.

afro.who.int

Emerging lessons from Africa’s COVID-19 vaccine rollout

Source: WHO Africa

WHO shine a light on key lessons emerging from African countries that have made strong progress, including Angola, Ghana, Mauritius and Rwanda.

health.go.ke

Kenya to Acquire Pfizer, Johnson and Johnson Vaccines says CS Kagwe 

Source: KMoH

Kenya’s Health Cabinet Secretary Mutahi Kagwe has said the government was pursuing the acquisition of one million doses of vaccines each from Pfizer as well as Johnson and Johnson respectively...

health.go.ke

Vaccine Clarification

Source: KMoH

In a statement, the Kenyan Ministry of Health’s National Taskforce for Vaccine Development clarifies some confusion over variance in Covishield vaccine dose administration.

jwatch.org

EU Regulators Call for Warning on J&J COVID-19 Vaccine

Source: NEJM

EU said on Tuesday that the J&J vaccine should come with a warning about the rare risk for thrombosis with thrombocytopenia.

jwatch.org

COVID-19 Vaccines: Safety in Pregnancy / J&J Data / Breakthrough Infections

Source: NEJM

Johnson & Johnson vaccine data results indicate that COVID-19 vaccination appears to be safe in the third trimester of pregnancy. 

jwatch.org

Further Information on Immune Thrombotic Thrombocytopenia Following SARS-CoV-2 Vaccination

Source: NEJM

Almost all patients with VITT  had anti–platelet factor 4 antibodies, which activly disrupt the normal clotting process, counterintuitively.

nejm.org

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

Source: NEJM

2 women out of a cohort of 417 persons who had received the second dose of Pfizer–BioNTech or Moderna vaccine identified with vaccine breakthrough infection.

nejm.org

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Source: NEJM

A single dose of Ad26.COV2.S protected against symptomatic COVID-19 and asymptomatic SARS-CoV-2 infection and was effective against severe–critical disease.

nejm.org

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons

Source: NEJM

Preliminary findings did not show obvious safety signals among pregnant persons who received mRNA COVID-19 vaccines. al, pregnancy, and infant outcomes.

thelancet.com

Recombinant protein vaccines against SARS-CoV-2

Source: Lancet

It is not unusual for vaccine development programmes to encounter difficulties, or have a need to revisit the vaccine design or dosing regimen.

thelancet.com

COVID-19 herd immunity by immunisation: are children in the herd?

Source: Lancet

Because individuals are not equally susceptible and contagious, current target to vaccinate 65–70% of the population for herd immunity might be an overestimate.

thelancet.com

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

Source: Lancet

This first-in-human trial shows that vaccine comprising MF59-adjuvanted (a chemical that helps create an emulsion of the active parts of the vaccine), spike protein all generated using mamalian cells, generates...

thelancet.com

COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room

Source: Lancet

Vaccine efficacy is generally reported as a relative risk reduction (RRR).

thelancet.com

Population immunity and vaccine protection against infection

Source: Lancet

The most direct pathway to population immunity is known as sterilising immunity. New study indicates the vaccine Pfizer-BioNTech provides substantial protection against infection

thelancet.com

2021: the beginning of a new era of immunisations?

Source: Lancet

The Immunization Agenda 2030 provides a new global vision and strategy for vaccines for the next decade.

thelancet.com

COVID-19 vaccines: building and maintaining confidence

Source: Lancet

Risk-benefit assessments for different groups should be redefined as safety data on rare events emerge.

thelancet.com

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study

Source: Lancet

In a trial of a new vaccine produced by Sanofi Pasteur, the lower than expected immune responses, especially in the older age groups, and the high generation of expected side...

thelancet.com

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study

Source: Lancet

Findings show that Pfizer-BioNTech can prevent both symptomatic and asymptomatic infection in working-age adults.

thelancet.com

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

Source: Lancet

Mass roll-out of first doses of Pfizer-BioNTech and Oxford-Astrazeneca vaccines was associated with substantial reductions in the risk of hospital admission due to COVID-19 in Scotland.

bmj.com

Covid-19: Unusual blood clots are “very rare side effect” of Janssen vaccine, says EMA

Source: BMJ

The EMA’s Pharmacovigilance Risk Assessment Committee has reviewed all available evidence including eight cases reported in the US, one of which had a fatal outcome. As of 13 April 2021...

bmj.com

Covid-19: Pregnant women should be offered Pfizer or Moderna vaccine, says UK advisory committee

Source: BMJ

Pregnant women should be offered the Pfizer BioNTech or Moderna COVID-19 vaccine at the same time as the rest of the population, with priority based on age and clinical risk...

bmj.com

Covid-19: Infections fell by 65% after first dose of AstraZeneca or Pfizer vaccine, data show

Source: BMJ

Infections of SARS-CoV-2 fell by 65% after a first dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines, preliminary results from a large UK surveillance study indicate.

africacdc.org

UPDATE: Statement to Member States regarding thromboembolic events after vaccination with Janssen COVID-19 vaccine (Johnson & Johnson)

Source: Africa CDC

Africa CDC released a statement of a safety signal for the Janssen COVID-19 vaccine following reports of extremely rare and unusual blood clots in combination with low platelets.

africacdc.org

Statement on donation and distribution of Oxford-AstraZeneca COVID-19 vaccine through AVATT

Source: Africa CDC

In mid-March, AVATT shipped 925,000 doses of Oxford-AstraZeneca COVID-19 vaccines to 13 African Union Member States.

cdc.gov

A safe and effective COVID-19 vaccine is now available

Source: US CDC

US CDC comic strip about COVID-19 Vaccines

cdc.gov

There are Different COVID-19 Vaccines

Source: US CDC

US CDC brief overview of COVID-19 vaccines

who.int

Continuing the fight: WHO donors and partners support COVID-19 response around the world

Source: WHO

Weekly highlight of the WHO’s activities in regions and countries with the support of Gavi, ECHO, Canada, USAID and other partners.

who.int

Global Advisory Committee on Vaccine Safety (GACVS) review of latest evidence of rare adverse blood coagulation events with AstraZeneca COVID-19 Vaccine (Vaxzevria and Covishield)

Source: WHO

TTS involving unusual and severe blood clotting events associated with low platelet counts reported after vaccination with COVID-19 Vaccines Vaxzevria and Covishield.

who.int

Statement of SAGE on Immunization: Continued review of emerging evidence on AstraZeneca COVID-19 Vaccines

Source: WHO

WHO continues to support the conclusion that the benefits of these vaccines outweigh the risks even after risk of Thrombosis has been added. 

jwatch.org

Immune Thrombotic Thrombocytopenia Linked to the AstraZeneca COVID-19 Vaccine

Source: NEJM

These studies provide evidence that the AstraZeneca vaccine can induce unusual autoantibodies that promote both thrombosis and thrombocytopenia (blood clotting event); however, incidence appears extremely low (

jwatch.org

Encouraging Findings About SARS-CoV-2 mRNA Vaccination During Pregnancy

Source: NEJM

Study can be utilized by clinicians to encourage hesitant pregnant women to receive vaccines. Optimal vaccine timing in these cases require further study.

jwatch.org

Helmet Non-invasive Ventilation Helped Patients with COVID-19 Avoid Intubation

Source: NEJM

Report on peer review article

jwatch.org

CDC Advisers Recommend Continuing Pause on J&J COVID-19 Vaccine

Source: NEJM

The CDC's Advisory Committee on Immunization Practices decided on Wednesday to continue recommending that vaccine providers pause use of J&J adenovirus-vectored COVID-19 vaccine.

jwatch.org

The AstraZeneca COVID-19 Vaccine vs. the SARS-CoV-2 B.1.1.7 Variant

Source: NEJM

Findings provide reassurance that, despite a drop-off in neutralizing antibody titers, the Oxford AstraZeneca vaccine continues to protect from infection by B.1.1.7 (UK) variant.

jwatch.org

Risk for Cerebral Venous Thrombosis Elevated After COVID-19 Diagnosis

Source: NEJM

In patients with COVID-19, the absolute risk for cerebral venous thrombosis (blood clots affecting the brain) in the 2 weeks after diagnosis was 39 events per million people — significantly...

nejm.org

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Source: NEJM

Protection conferred by the mRNA-1273 (Moderna) vaccine against the P.1 (Brazilian), B.1.427/B.1.429 (Californian), and B.1.351 (South African) variants remains to be determined.

nejm.org

SARS-CoV-2 Antibody Response in Persons with Past Natural Infection

Source: NEJM

Whether or not persons who have already been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) should be vaccinated is unclear.

nejm.org

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

Source: NEJM

Case study of a women who suffered extreme thrombosis and thrombocytopenia (types of blood clotting events) after receiving the Janssen vaccine.

nejm.org

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Source: NEJM

Vaccination with ChAdOx1 nCov-19 (Oxford AstraZeneca) can result in the rare development of immune thrombotic thrombocytopenia (type of blood clotting event) mediated by platelet-activating antibodies against PF4, which clinically mimics...

nejm.org

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

Source: NEJM

A 48-year-old White woman with an unremarkable medical history presented to the emergency department with a 3-day history of malaise and abdominal pain. The initial evaluation at another hospital showed...

nejm.org

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer

Source: NEJM

Evidence is insufficient to establish a causal relationship between cerebral venous sinus thrombosis (CVST) (blood clotting event) and the Ad26.COV2.S (Oxford AstraZeneca) vaccine.

thelancet.com

Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2

Source: The Lancet

Neutralisation activity in 24 serum samples from participants in two clinical trials, 12 who had been vaccinated with BBIBP-CorV and 12 who had been vaccinated with ZF2001 (two COVID-19 vaccines...

thelancet.com

SARS-CoV-2 incidence and vaccine escape

Source: The Lancet

Reducing cases is not only beneficial for decreasing the pressure on health-care systems, but also for lowering the vaccine escape risk.

thelancet.com

Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination

Source: The Lancet

A 51-year-old woman attended our emergency department with a 3-day history of dyspnoea, fatigue, and cough and was found to have severe thrombocytopenia (abnormally low level of platelets. 11 days...

bmj.com

Covid-19: Rare immune response may cause clots after AstraZeneca vaccine, say researchers

Source: BMJ

Two teams of researchers have published detailed observations of patients who developed thrombotic thrombocytopenia (a rare blood clotting disorder) after receiving the AstraZeneca vaccine and have speculated about a possible...

bmj.com

Covid-19: EU investigates four reports of blood clots after Janssen vaccine

Source: BMJ

The EU is investigating four reported cases of unusual blood clots with low platelets in people who have received the J&J COVID-19 vaccine.

bmj.com

Covid-19: Chinese vaccines may need changes to improve efficacy, admits official

Source: BMJ

China may need to replace its coronavirus vaccines or change the way they are administered in order to make them sufficiently effective against the SARS-Cov2 virus.

bmj.com

Covid-19: US suspends Johnson and Johnson vaccine rollout over blood clots

Source: BMJ

US regulators have paused the rollout of the J&J COVID-19 vaccine after reports of a small number of blood clot cases in those who had been vaccinated.

bmj.com

Covid-19: Moderna and Novavax vaccines to be tested in mixing vaccines trial

Source: BMJ

The Moderna and Novavax COVID-19 vaccines will be added to a trial that is investigating the effect of mixing vaccines.

bmj.com

Covid-19: US reports low rate of new infections in people already vaccinated

Source: BMJ

The low rate of new infections in the US gives reassurance that the promising results seen in clinical studies of the Pfizer and Moderna vaccines, which account for the overwhelming...

bmj.com

Thrombosis after covid-19 vaccination

Source: BMJ

At the time of writing, six cases of serious thrombosis with thrombocytopenia (a blood clotting event) had been reported after the use of the Johnson & Johnson (Janssen) COVID-19 vaccine....

bmj.com

Covid-19: India authorises Sputnik V vaccine as cases soar

Source: BMJ

India’s regulators authorised the Russian made Sputnik V vaccine for emergency use, making it the third COVID-19 vaccine to be made available.

bmj.com

Covid-19: Risk of cerebral blood clots from disease is 10 times that from vaccination, study finds

Source: BMJ

COVID-19 is associated with a far greater risk of cerebral venous thrombosis (blood clot of a cerebral vein in the brain) than the vaccinations that protect against it, early research...

bmj.com

Single dose of Pfizer or AstraZeneca vaccine produces strong antibody response in over 80s

Source: BMJ

A small study looking at people over 80 has found that a single dose of the Pfizer or Oxford-AstraZeneca COVID-19 vaccine produces equivalent antibody responses five weeks after vaccination.

bmj.com

Covid-19: Vaccine woes highlight vital role of traditional public health

Source: BMJ

Vaccination remains a source of great hope, and in the UK the programme has showcased what the NHS can do when given the remit and resources. But, despite its early...

blogs.bmj.com

How will covid-19 vaccine safety concerns impact vaccine confidence?

Source: BMJ

Survey in the UK illustrates a drop in confidence in the safety of the AstraZeneca COVID-19 vaccine compared with two weeks previously.

england.nhs.uk

JCVI announcement regarding COVID-19 vaccination during pregnancy and next steps

Source: NHS

JCVI advises that it’s preferable for pregnant women in the UK to be offered the Pfizer-BioNTech or Moderna vaccines where available.

africacdc.org

CEPI and the African Union join forces to boost African vaccine R&D and manufacturing

Source: Africa CDC

CEPI aims to work with low-income and middle-income countries to develop the infrastructure and expertise to undertake the epidemiological and clinical studies needed to advance vaccine development, support technology transfer,...

africacdc.org

Statement to Member States regarding thromboembolic events after vaccination with Janssen COVID-19 vaccine (Johnson & Johnson)

Source: Africa CDC

The Africa Regulatory Taskforce has endorsed the Emergency Use Authorization for the Janssen COVID-19 vaccine. In African member states, the Janseen vaccine is currently only in use in South Africa,...

africacdc.org

African Union and Africa CDC launches Partnerships for African Vaccine Manufacturing (PAVM), framework to achieve it and signs 2 MoUs

Source: Africa CDC

African Union Heads of State and over 40,000 participants attended a virtual summit on Expanding Africa’s Vaccine Manufacturing for Health Security.

who.int

Global Advisory Committee on Vaccine Safety (GACVS) review of latest evidence of rare adverse blood coagulation events with AstraZeneca COVID-19 Vaccine (Vaxzevria and Covishield)

Source: WHO

Data from the UK suggest the risk is approximately1 case per 250 000 who receive the vaccine, while the rate is estimated to be approximately 1 per 100 000 in...

afro.who.int

Bolstering vigilance as Africa rolls out COVID-19 vaccine

Source: WHO Africa

More than 13.6 million, including 12 million AstraZeneca, vaccine doses have been administered in Africa. Side effects reported range from mild to moderate.

fullfact.org

Covid vaccine hasn’t caused increase in care home deaths

Source: FullFact

Claim:  Deaths in care homes are up 81% since the start of the Covid-19 vaccination rollout. Verdict: Deaths in care homes are up considerably, although we haven’t been able to...

snopes.com

Can You Buy COVID-19 Vaccines on the Dark Web?

Source: SNOPES

Claim: COVID-19 vaccines are for sale on the dark web. Verdict: On some dark web marketplaces, there are listings for COVID-19 vaccines. These listings are almost always — if not...

cdc.gov

Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States

Source: US CDC

Very detailed report on reasons and circumstances to withhold vaccines (contraindications) from certain patients.  Appendix B has a triage chart for vaccination and Appendix C has a full list of...

jwatch.org

A Protein Subunit SARS-CoV-2 Vaccine Seems Likely

Source: NEJM

Discussion of research articles A new vaccine, in development, that mimics the spike protein of SARS-CoV-2 is looking promising. Original paper published 29th Jan in the Lancet

who.int

AZD1222 vaccine against COVID-19 developed by Oxford University and Astra Zeneca: Background paper (draft)

Source: WHO

This document provides the background evidence related to the Interim recommendations for use of the AZD1222 (ChAdOx1-S [recombinant]) vaccine against COVID-19 developed by Oxford University and AstraZeneca.

fda.gov

WHO Recommends AstraZeneca-Oxford COVID-19 Vaccine

Source: NEJM

The WHO on Wednesday issued an interim recommendation in favor of the AstraZeneca-Oxford adenovirus-vectored COVID-19 vaccine. The agency advises that adults aged 18 and older receive two doses, spaced 8...

cdc.gov

COVID-19 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination — United States, September and December 2020

Source: US CDC

Pre release of research article Ensuring high and equitable vaccination coverage among all populations, including by addressing reasons for not intending to receive vaccination, is critical to prevent the spread...

jwatch.org

COVID-19 Vaccines: Americans’ Intent to Be Vaccinated / Recommendations in Pregnancy

Source: NEJM

Report on Research article The proportion of Americans who said they were "absolutely certain" or "very likely" to be vaccinated against COVID-19 if a vaccine were available rose from 39%...

jwatch.org

Officials Investigating Reports of Thrombocytopenia After COVID-19 Vaccine

Source: NEJM

Report from New York times Out of 31 million people who've received at least one vaccine dose, nearly 40 cases of thrombocytopenia (low level of platelets in the bloodstream reducing...

thelancet.com

Tanzania refuses COVID-19 vaccines

Source: The Lancet

On Feb 2, 2021, in Dodoma, Tanzania's capital, the health minister announced that the country “has no plans in place to accept COVID-19 vaccines”.  The message follows days after President...

thelancet.com

SARS-CoV-2 vaccines: fast track versus efficacy

Source:

Opinion piece  Unprecedented as the COVID-19 pandemic might have been, more variants of SARS-CoV-2 will enter circulation and zoonotic pathogens (diseases that have crossed the species barrier) will arise.  Fast-tracking...

bmj.com

Why did a German newspaper insist the Oxford AstraZeneca vaccine was inefficacious for older people—without evidence?

Source: BMJ

Opinion piece Reporting information from single anonymous sources that turns out to be false could erode public confidence in the vaccines that are crucial to controlling the COVID-19 pandemic.  Handelsblatt...

africacdc.org

Statement on the Efficacy of the AstraZeneca COVID-19 Vaccine (ChAdOx1 nCoV-19) against the SARS-CoV-2 Variants

Source: Africa CDC

For countries that have NOT reported the circulation of the SARS-CoV-2 N501Y.V2 (or B.1.351), we recommend proceeding with the rollout of the AstraZeneca vaccine. For countries that HAVE reported the...

jwatch.org

COVID-19 Vaccine: WHO OK’s AstraZeneca Vaccine for Emergency Use

Source: NEJM

The WHO gave Oxford-AstraZeneca's COVID-19 vaccine an emergency use listing, meaning it can be administered through its COVID-19 Vaccines Global Access (COVAX) program.

jwatch.org

COVID-19 Vaccines: Reduced Activity Against B.1.351 Strain / Delaying Second Dose?

Source: NEJM

Comment on pre-release The Pfizer-BioNTech and Moderna COVID-19 vaccines show reduced effectiveness in neutralizing the highly transmissible SARS-CoV-2 variant B.1.351 that was first identified in South Africa, according to serum...

nejm.org

Neutralizing Activity of BNT162b2-Elicited Serum — Preliminary Report

Source: NEJM

Report on research article In a randomized, placebo-controlled clinical trial involving approximately 44,000 participants, immunization conferred 95% efficacy against coronavirus disease 2019 (Covid-19). It is unclear what the  effect of...

nejm.org

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report

Source: NEJM

Report on research article The mRNA-1273 vaccine against SARS-CoV-2 elicited high neutralizing-antibody titers in phase 1 trial participants and has been shown to be highly efficacious in preventing symptomatic COVID-19...

ecdc.europa.eu

Risk assessment: SARS-CoV-2 – increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update

Source: EU CDC

This risk assessment provides an overall update on the COVID-19 situation in the EU/EEA, including latest data on the situation with SARS-CoV-2 variants of concern covered by previous targeted risk...

thelancet.com

What does 95% COVID-19 vaccine efficacy really mean?

Source: The Lancet

Opinion piece It means that in a population such as the one enrolled in the trials, with a cumulated COVID-19 attack rate over a period of 3 months of about...

bmj.com

Covid-19: Is vaccination roll out reducing cases and deaths in the UK?

Source: BMJ

Opinion piece Experts agree that although signs are encouraging better data are needed.  Duncan Robertson, an analyst from Loughborough University’s School of Business and Economics,  said, “The vaccination rollout data...

bmj.com

Covid-19: No evidence that vaccines can affect fertility, says new guidance

Source: BMJ

Opinion piece There is “absolutely no evidence” that COVID-19 vaccines can affect the fertility of women or men, says new expert guidance. “We’ve seen a lot of blatant misinformation that...

nhs.uk

Coronavirus (COVID-19) vaccine

Source: NHS

Update on vaccinations and side effects

cdc.gov

Selected Adverse Events Reported after COVID-19 Vaccination

Source: US CDC

Results from monitoring efforts are reassuring. Some people have no side effects. Many people have reported only mild side effects after COVID-19 vaccination.

cdc.gov

Safety of COVID-19 Vaccines

Source: US CDC

Millions of people have safely received a COVID-19 vaccine. COVID-19 vaccines are safe and effective.

cdc.gov

COVID-19 Vaccine Effectiveness Research

Source: US CDC

An overview of the studies being carried out by the CDC in studying the effectiveness of COVID-19 Vaccines

cdc.gov

What to Expect after Getting a COVID-19 Vaccine

Source: US CDC

You may have some side effects, which are normal signs that your body is building protection.  These side effects may affect your ability to do daily activities, but they should...

cdc.gov

Detection of B.1.351 SARS-CoV-2 Variant Strain — Zambia, December 2020

Source: US CDC

Pre-release paper Expanding capacity for genetic epidemiology in Africa will help strengthen surveillance for the B.1.351 variant as well as early detection of emerging variants that might affect the implementation...

cdc.gov

What Older Adults Need to Know about COVID-19 Vaccines

Source: US CDC

The risk of severe illness from COVID-19 increases with age.  This is why CDC recommends that adults 65 years and older are one of the first groups to receive COVID-19...

cdc.gov

Communication Resources for COVID-19 Vaccines

Source: US CDC

Two resource packs available for communicating to the public about vaccination and also a social media toolkit.

cdc.gov

First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021

Source: US CDC

Pre-release paper Health care providers and vaccine recipients can be reassured about the safety of Pfizer BioNTech and Moderna COVID-19 vaccines.  Counselling vaccine recipients to expect minor discomfort (e.g. swelling)...

cdc.gov

Frequently Asked Questions about COVID-19 Vaccination

Source: US CDC

This article provides answers to commonly asked questions about COVID-19 vaccination.  CDC also has information for busting common vaccine myths available as facts about COVID-19 vaccines.

who.int

G7 leaders commit US$ 4.3 billion to finance global equitable access to tests, treatments and vaccines in 2021

Source: WHO

Commitments made at today’s Virtual G7 leaders meeting hosted by UK Prime Minister Boris Johnson, and at the Munich Security Conference later in the day, signalled significant progress in the...

who.int

Country readiness for COVID-19 vaccines

Source: WHO

This article is part six in a series of explainers on vaccine development and distribution. This document outlines the next part of the vaccine journey: how countries are getting ready...

who.int

The Oxford/AstraZeneca COVID-19 vaccine: what you need to know

Source: WHO

This article provides a summary of the interim recommendations for use of the Oxford/AstraZeneca COVID-19 vaccine with links to the full guidance document While vaccine supplies are limited, it is...

afro.who.int

Africa is getting ready to roll out COVID-19 vaccines

Source: WHO Africa

Africa marked the move from planning to action in the rollout of COVID-19 vaccines at a World Health Organization (WHO)-hosted African Health Ministers meeting on 17 February. A rapid vaccine...

fullfact.org

There is no evidence that people are dying from the Covid-19 vaccine

Source: FullFact

Claim: Reports to the Yellow Card scheme suggest that the Covid vaccine from AstraZeneca is not safe. Verdict: This is not true. The Yellow Card scheme has collected reports of...

fullfact.org

Moderna’s Covid-19 vaccine will not change your DNA

Source: FullFact

Claim: Moderna’s COVID-19 vaccine is designed to change people’s DNA. Verdict: False. mRNA vaccines like Moderna’s instruct cells in the body to make proteins. They do not change their DNA.

snopes.com

mRNA COVID-19 Vaccines won’t wreak ‘Havoc on The Lungs’ in 4 to 14 months

Source: Snopes

Claim COVID-19 mRNA vaccines will become deadly a few months after administration because the antibodies they create have been shown to cause deadly immune reactions resulting in damage to the...

health.go.ke

PS MOCHACHE LAUNCHES COVID-19 VACCINATION

Source: KMoH

Kenya’s Principal Secretary Ms Susan Mochache launched the nationwide COVID-19 vaccination campaign at the Kenyatta National Hospital. During the event, the Ministry’s Director General Dr Patrick Amoth led the health...

health.go.ke

CS KAGWE RECEIVES FIRST COVID-19 VACCINE CONSIGNMENT

Source: KMoH

Health Cabinet Secretary Senator Mutahi Kagwe received a consignment of 1.2 million doses of Astrazeneca COVID-19 Vaccines at the JomoKenyatta International Airport.

jwatch.org

Considerable Protective Immunity May Persist for 7 Months After COVID-19

Source: NEJM

Report on peer reviewed article Immunity to SARS-CoV-2 lasted for at least 7 months in the vast majority of convalescents, comparing nicely with the effectiveness of the Moderna and Pfizer...

jwatch.org

COVID-19 Vaccines: Missing Race & Ethnicity Data / Single-Dose Effectiveness / J&J Recommendations

Source: NEJM

One dose of the Pfizer-BioNTech or AstraZeneca-Oxford vaccine offers substantial protection against COVID-19, according to a preprint study posted online. The CDC's recommendations for use of the J&J adenovirus-vectored COVID-19...

jwatch.org

Pfizer COVID-19 mRNA Vaccine’s Real-World Performance

Source: NEJM

Investigators utilized data from Clalit Health Services, which provides healthcare to 53% of Israel's population, to determine the effectiveness of the two-dose Pfizer BNT162b2 mRNA vaccine in preventing COVID-19. Each...

jwatch.org

Coverage of COVID-19 This Week

Source: NEJM

This week, NEJM Journal Watch covered COVID-19–related topics including real-world performance of the Pfizer mRNA vaccine, household air contamination with SARS-CoV-2, enduring protective immunity after COVID-19, secondary infections in patients...

jwatch.org

COVID-19 Vaccine: Delayed Large Local Reactions Possible

Source: NEJM

A series of delayed skin reactions in 12 patients after receiving the Moderna mRNA vaccine are described in the New England Journal of Medicine.

jwatch.org

COVID-19 Vaccines: J&J Clinical Considerations / Polysorbate / Post-Vaccine COVID

Source: NEJM

The CDC has updated its interim clinical considerations for use of the COVID-19 vaccines authorized in the United States. The CDC also noted that people who've recovered from COVID-19 may...

thelancet.com

The world’s largest COVID-19 vaccination campaign

Source: The Lancet

As of Feb 8, more than 6 million people have been vaccinated in the world's largest COVID-19 vaccination campaign that started on Jan 16 in India. The first vaccine was...

thelancet.com

An interactive website tracking COVID-19 vaccine development

Source: The Lancet

Launched in April 2020, this tracker aims to collate up-to-date information on all COVID-19 vaccine candidates from inception through to deployment, enabling policy makers, researchers, and the public to keep...

thelancet.com

Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster

Source: The Lancet

A report published in response to a peer reviewed article, finds that a single dose of the CoV-19 vaccine is highly effective in the 90 days after vaccination, and that...

thelancet.com

Challenges in the rollout of COVID-19 vaccines worldwide

Source: The Lancet

COVAX hopes to deliver more than 2 billion doses of the vaccines in 2021. At least 1.3 billion doses are earmarked for the 92 low-income and middle-income countries (LMICs) eligible...

bmj.com

Covid-19: Single dose of Pfizer and Oxford vaccines cuts risk of hospital admission by 80% in over 80s, data suggest

Source: BMJ

Analysis by Public Health England (PHE), published as a preprint, estimated that a single dose of either vaccine is around 80% effective at preventing hospital admission in people aged over...

bmj.com

Covid-19: Where are we on vaccines and variants?

Source: BMJ

Pfizer and Oxford-AstraZeneca are reported to be in discussions regarding updating their vaccines to target new variants. Meanwhile, Moderna has said it is waiting on approval from regulators to start...

bmj.com

Covid-19: 237m vaccine doses to be distributed worldwide over next three months

Source: BMJ

Covax is a multilateral initiative aimed at ensuring that all countries have “fair and equitable access” to COVID-19 vaccines. Covax announced on 2 March that Cote d’Ivoire, Ghana, and India...

cdc.gov

Media Statement from CDC Director Rochelle P. Walensky, MD, MPH, on Signing the Advisory Committee on Immunization Practices’ Recommendation to Use Janssen’s COVID-19 Vaccine in People 18 and Older

Source: US CDC

The J&J/Janssen vaccine is an important tool in our toolbox to equitably vaccinate as many people as possible, as quickly as possible. As a one-dose vaccine, people do not have...

cdc.gov

Selected Adverse Events Reported after COVID-19 Vaccination

Source: US CDC

A selection of results from monitoring efforts have been found by the CDC to be reassuring. Some people have no side effects. Many people have reported only mild side effects...

cdc.gov

Understanding Viral Vector COVID-19 Vaccines

Source: US CDC

Viral vector vaccines use a modified version of a different virus (the vector) to deliver important instructions to our cells. For COVID-19 viral vector vaccines, the vector (not the virus...

cdc.gov

Social Media Toolkit: COVID-19 Vaccinations

Source: US CDC

Social media resources for Facebook, Instagram and Twitter for information on COVID-19 Vaccinations.

cdc.gov

Janssen COVID-19 Vaccine (Johnson & Johnson) Questions

Source: US CDC

Overview of detail of the Janssen COVID-19 (Johnson & Johnson) vaccine. Learn more about how CDC is making COVID-19 vaccine recommendations.

cdc.gov

COVID-19 Vaccine Monitoring Systems for Pregnant People

Source: US CDC

If you are pregnant, you might choose to be vaccinated when a vaccine is available to you. Currently, there is no evidence that COVID-19 vaccination causes any problems with pregnancy,...

cdc.gov

Different COVID-19 Vaccines

Source: US CDC

Learn how the body fights infection and how COVID-19 vaccines protect people by producing immunity. Also see the different types of COVID-19 vaccines that currently are available or are undergoing...

cdc.gov

Understanding mRNA COVID-19 Vaccines

Source: US CDC

COVID-19 mRNA vaccines give instructions for our cells to make a harmless piece of what is called the “spike protein.” Our immune systems recognize that the protein doesn’t belong there...

cdc.gov

What to Do if You Have an Allergic Reaction After Getting A COVID-19 Vaccine

Source: US CDC

If you had a severe allergic reaction—also known as anaphylaxis—after getting the first shot of a COVID-19 vaccine, CDC recommends that you not get a second shot of that vaccine....

cdc.gov

Information about the Pfizer-BioNTech COVID-19 Vaccine

Source: US CDC

The Pfizer-BioNTech vaccine is recommended for people aged 16 years and older. Learn more about how CDC is making COVID-19 vaccine recommendations.

cdc.gov

Information about the Moderna COVID-19 Vaccine

Source: US CDC

The Moderna vaccine is recommended for people aged 18 years and older. Learn more about how CDC is making COVID-19 vaccine recommendations

cdc.gov

Information about COVID-19 Vaccines for People with Allergies

Source: US CDC

An allergic reaction is considered severe when a person needs to be treated with epinephrine or EpiPen© or if the person must go to the hospital. Experts refer to severe...

cdc.gov

Information About Johnson & Johnson’s Janssen COVID-19 Vaccine

Source: US CDC

The J&J/Janssen vaccine is recommended for people aged 18 years and older. Learn more about how CDC is making COVID-19 vaccine recommendations.

cdc.gov

Importance of COVID-19 Vaccination for Residents of Long-term Care Facilities

Source: US CDC

All COVID-19 vaccines were tested in clinical trials involving tens of thousands of people to make sure they meet safety standards and protect adults of different races, ethnicities, and ages,...

cdc.gov

Vaccine Considerations for People with Underlying Medical Conditions

Source: US CDC

COVID-19 vaccines may be administered to most people with underlying medical conditions (including HIV, Bell’s Palsy, Guillain-Barre syndrome (GBS), and issues with the immune system) once a vaccine is available...

cdc.gov

Possible Side Effects After Getting a COVID-19 Vaccine

Source: US CDC

COVID-19 vaccination will help protect you from getting COVID-19. You may have some side effects, which are normal signs that your body is building protection.  These side effects may affect...

cdc.gov

COVID-19 Science Update released: March 5, 2021 Edition 79

Source: US CDC

A round up of recent scientific research and factual reports.

who.int

First COVID-19 COVAX vaccine doses administered in Africa

Source: WHO

The campaigns in Ghana and Côte d’Ivoire followed deliveries to both countries last week with Ghana taking delivery of 600 000 doses on February 24 and Côte d’Ivoire 504 000...

who.int

COVAX publishes first round of allocations

Source: WHO

Following from the publication of an interim distribution forecast, and based on current knowledge of supply availability, this first round of allocations provides information on provision of doses of the...

afro.who.int

WHO Statement on the Catholic Doctors Association of Kenya Advisory on COVID‐19 Vaccines and Treatment

Source: WHO Africa

The AstraZeneca vaccine produced by the Serum Institute of India and now being distributed in Kenya, has been reviewed and found safe not only by the WHO’s rigorous process but...

afro.who.int

Angola becomes the first country in Eastern and Southern Africa region to receive COVAX vaccines against COVID-19

Source: WHO Africa

Angola today received 624,000 doses of the AstraZeneca-Oxford vaccine from the Sérum Institute of India as part of the COVAX initiative, which aims to ensure the equitable distribution of vaccines...

afro.who.int

Ghana’s President receives first shot of historic COVAX vaccine to launch vaccination campaign

Source: WHO Africa

The President of the Republic, Nana Addo Dankwa Akufo-Addo together with his wife, Mrs. Rebecca Akufo-Addo received the first shots of the vaccine. He described his decision as an important...

afro.who.int

First COVID-19 COVAX vaccine doses administered in Africa

Source: WHO Africa

As the global rollout of COVAX vaccines accelerates, the first COVID-19 vaccination campaigns in Africa using COVAX doses began today (1 March) in Ghana and Côte d'Ivoire. These campaigns are...

afro.who.int

96,000 Doses of COVID-19 Vaccine Arrives in Liberia

Source: WHO Africa

Margibi, Liberia, 05 March 2021 - Liberia received 96,000 COVID-19 vaccine doses shipped via the COVAX initiative, a partnership between CEPI, Gavi, UNICEF and WHO.

jwatch.org

High Antibody Response after First COVID-19 mRNA Vaccine Dose in Those Previously Infected

Source: NEJM

Report on peer review article People with prior COVID-19 infection show high immune response after only one mRNA vaccine dose, according to data published in the New England Journal of...

jwatch.org

COVID-19 Vaccines: Allergic Reactions / Dr. B’s Extra Doses / Antibodies in Neonatal Cord Blood

Source: NEJM

Some of the latest news on the COVID-19 vaccines, including Allergic reactions to the Pfizer-BioNTech or Moderna mRNA vaccines and new findings on vaccination during pregnancy.

thelancet.com

Adjuvantation helps to optimise COVID-19 vaccine candidate

Source: The Lancet

Opinion piece In trials of two other alum-adjuvanted inactivated vaccines, the overall efficacy of BBIBP-CorV is approximately 79·3% and of CoronaVac is approximately 50·4%, and both vaccines reportedly provide 100%...

thelancet.com

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Source: The Lancet

Peer review article In the phase 1 trial, BBV152 induced high antibody responses that remained elevated in all participants at 3 months after the second vaccination. In the phase 2...

thelancet.com

Addressing challenges to rolling out COVID-19 vaccines in African countries

Source: The Lancet

Opinion piece There is much ongoing debate and concern regarding access to COVID-19 vaccines and roll-out gaps in low-income and middle-income countries compared with high-income countries. African countries, many of...

thelancet.com

Could a good night’s sleep improve COVID-19 vaccine efficacy?

Source: The Lancet

Opinion piece As suggested by previous studies, sleep duration at the time of vaccination against viral infections can affect the immune response.

thelancet.com

Access to COVID-19 vaccines: looking beyond COVAX

Source: The Lancet

Opinion piece COVAX is unequipped to resolve many of the most pressing threats to its mission. Global vaccination is central to ending the pandemic, yet it has been dealt with...

cdc.gov

Key Things to Know About COVID-19 Vaccines

Source: US CDC

Studies show that COVID-19 vaccines are effective at keeping you from getting COVID-19. Getting a COVID-19 vaccine will also help keep you from getting seriously ill even if you do...

cdc.gov

When You’ve Been Fully Vaccinated

Source: US CDC

CDC guidelines on how to protect yourself and others once you have been fully vaccinated, as well as some notes on what we know and what we are still learning...

cdc.gov

COVID-19 vaccination and other medical procedures

Source: US CDC

American CDC guidance on routine medical procedures or screenings that can be performed before or after getting a COVID-19 vaccine.

africacdc.org

COVID 19 Vaccine Perceptions: A 15 country study

Source: Africa CDC

Reported willingness to accept a COVID-19 vaccine was highly variable across the 15 African countries surveyed, with significant regional differences. Intent to accept a COVID-19 vaccine ranges from higher acceptance...

africacdc.org

Report: Virtual Meeting on The African COVID-19 Vaccine Financing and Deployment Strategy

Source: Africa CDC

Report on the African Centre for Disease Control’s (CDC) virtual meeting on COVID-19 Vaccine Financing and Deployment Strategy and key points

africacdc.org

African Union and the Africa Centers for Disease Control and Prevention’s Africa Regulatory Task Force has endorsed the Emergency Used Authorization for Janssen COVID-19 Vaccine

Source: Africa CDC

In order to properly guide Member States, the Africa Regulatory Taskforce has developed a framework for market authorisation of COVID-19 vaccines, which include three scenarios which are outlined in the...

who.int

WHO adds Janssen vaccine to list of safe and effective emergency tools against COVID-19

Source: WHO

The WHO today listed the COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson & Johnson), for emergency use in all countries and for COVAX roll-out. The decision comes on the back...

who.int

ACT-Accelerator releases prioritised strategy and budget for 2021 to change the course of the evolving COVID-19 pandemic

Source: WHO

In under a year, the ACT Accelerator has driven real progress to accelerate the end of the COVID-19 pandemic. It has accelerated the development of COVID-19 tests, treatments, vaccines and...

who.int

GACVS COVID-19 Vaccine Safety subcommittee meeting to review reports on influenza-like illness in individuals vaccinated with COVID-19 vaccines

Source: WHO

Symptoms of an influenza-like illness may be expected as immune responses following vaccinations in general. The current reports with the COVID-19 vaccines are consistent with the expected side-effect profile of...

afro.who.int

COVID-19 cases in Africa to top 4 million, vaccine rollout underway

Source: WHO Africa

COVID-19 vaccine deliveries are picking up speed, the response to the pandemic is getting a much-awaited boost. More than 14.6 million vaccine doses have been delivered to 22 African countries...

afro.who.int

Ethiopia introduces COVID-19 vaccine in a national launching ceremony

Source: WHO Africa

The first shipment of the AstraZeneca vaccines produced by the Serum Institute of India (SII) arrived in Ethiopia on 6 March 2021 through COVAX, which facilitated the procurement and shipment...

afro.who.int

Public health experts elated with COVID-19 vaccine delivery, assure Nigerians of vaccine effectiveness and safety.

Source: WHO Africa

On 02 March 2021, Nigeria received nearly 4 million doses of the COVID-19 vaccine, shipped via the COVAX Facility, a partnership between CEPI, Gavi, UNICEF and WHO. The consignment for...

poynter.org

European fact-checkers try to explain the confusing move to stop using the AstraZeneca vaccine

Source: Poynter

European fact-checkers are trying to explain the confusing move to pause administration of the AstraZeneca vaccine. They say the lack of scientific evidence justifying the move is giving oxygen to...

poynter.org

Why European governments took a closer look at AstraZeneca’s COVID-19 vaccine

Source: Poynter

There have been relatively few cases of blood clots — a few dozen among the 17 million people who have been vaccinated in Europe and the United Kingdom — and...

snopes.com

Marvellous Marvin Hagler Did Not Die From COVID-19 Vaccination?

Source: Snopes

Claim: Marvellous Marvin Hagler's death in March 2021 was caused by his receiving a COVID-19 vaccination. Rating: False. This claim has been refuted by Marvellous Marvin Hagler’s wife.

fullfact.org

17 countries haven’t ‘banned’ the Oxford-AstraZeneca vaccine

Source: FullFact

Claim: Seventeen countries have banned the AstraZeneca vaccine outside of the UK. Verdict: This is not the case. At the time of writing, 17 countries in Europe have temporarily stopped...

snopes.com

Does AstraZeneca COVID-19 Vaccine Cause Blood Clots?

Source: Snopes

Claim:  Does the AstraZeneca COVID-19 vaccine cause blood clots? We did not apply a traditional truth rating to this claim, as this matter is still under review. The European Medicines...

snopes.com

Is Horseshoe Crab Blood Required for COVID-19 Vaccines?

Source: Snopes

Claim: The blue blood of horseshoe crabs is required for the production of COVID-19 vaccines. Rating: Partly true. A chemical compound found in the blood of horseshoe crabs is widely...

snopes.com

Does Drinking Alcohol Impair Effectiveness of COVID-19 Vaccine?

Source: Snopes

Claim:  Drinking alcohol between COVID-19 doses can impair the effectiveness of the immunization. Verdict: Research In Progress. There is currently no formal recommendations to avoid alcohol before or after receiving...

kemri.org

KEMRI’s DG receives COVID-19 Vaccine jab

Source: KEMRI

KEMRI ‘s Acting Director General, Prof. Sam Kariuki received his Oxford AstraZeneca vaccine jab this Tuesday, 16th March 2021 at Mbagathi Hospital. The clinical trials which are on the third...

health.go.ke

CS KAGWE Receives more COVID-19 Vaccines from India

Source: KMoH

Health Cabinet Secretary Senator Mutahi Kagwe received 100,000 Astrazeneca vaccine consignments from India at JomoKenyatta International Airport on Thursday evening.

health.go.ke

CAS MWANGANGI gets COVID-19 jab

Source: KMoH

Chief Administrative Secretary Dr Mercy Mwangangi today received her COVID-19 vaccination at Kenyatta National Hospital.

jwatch.org

COVID-19 Vaccines: Blood Clot Investigation / All Adults Eligible by May / WHO Authorizes J&J Vaccine

Source: NEJM

Several European countries have temporarily halted use of the AstraZeneca/Oxford COVID-19 vaccine after reports of blood clots in people recently vaccinated, news outlets report. The European Medicines Agency said that...

nejm.org

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Source: NEJM

Report on peer reviewed article The Moderna (mRNA-1273) vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicited high neutralizing-antibody titers in phase 1 trial participants and has been...

jwatch.org

COVID-19 Vaccines: AstraZeneca on Blood Clots / Second-Dose Delivery / Skilled Nursing Facilities

Source: NEJM

AstraZeneca issued a statement on Sunday to reassure the public about the safety of its COVID-19 vaccine after several European Union countries halted its use over concerns about blood clots....

jwatch.org

COVID-19 Vaccines: AstraZeneca & B.1.351 / Response in Transplant Recipients / Moderna & Young Children

Source: NEJM

Report on peer reviewed article AstraZeneca's COVID-19 vaccine does not appear to prevent infection from the B.1.351 variant, according to a study. Moderna says it has begun testing its mRNA...

jwatch.org

Allergic Reactions to COVID-19 mRNA Vaccines

Source: NEJM

Report on peer reviewed article Two reports reaffirm the low incidence of severe reactions to either mRNA vaccine — although we still need clarity about the mechanisms of anaphylactoid reactions...

jwatch.org

Weighing the Timing of the Oxford/AstraZeneca Vaccine’s Second Dose

Source: NEJM

Report on peer reviewed article Pooled analysis showed vaccine efficacies of 76.0% after a single dose of AZD1222 and 81.3% after a booster given ≥12 weeks after the first dose.

jwatch.org

COVID-19 Vaccines: WHO Recommends J&J, Says AstraZeneca Benefits Outweigh Risks

Source: NEJM

The WHO on Wednesday officially recommended Johnson & Johnson's single-dose COVID-19 vaccine for adults aged 18 years and older. The agency also said that it considers the benefits of the...

jwatch.org

How Well Does the Oxford/AstraZeneca Vaccine Stand Up Against the South African SARS-CoV-2 Variant?

Source: NEJM

Report on peer reviewed article In a trial in South Africa, the AZD1222 vaccine did not protect against mild-to-moderate COVID-19 caused by the B.1.351 variant. These findings reinforce the need...

jwatch.org

European Regulators: Benefits of AstraZeneca COVID-19 Vaccine Outweigh Potential Risks

Source: NEJM

The regulatory agency said that while the vaccine is not associated with overall risk for thromboembolic events, it could not rule out an increased risk for "very rare cases of...

thelancet.com

Free licensing of vaccines to end the COVID-19 crisis

Source: Lancet

Opinion piece Ideally, an agreement could be reached with the patent holders to make the relevant intellectual property available. However, if this agreement is not possible, compulsory licensing is possible...

thelancet.com

Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study

Source: Lancet

Peer review article Vaccines against SARS-CoV-2 offer a potential exit strategy for the pandemic, success is highly contingent on the precise vaccine properties and population uptake, both of which need...

bmj.com

Covid-19: Stronger warnings are needed to curb socialising after vaccination, say doctors

Source: BMJ

Experts have called for stronger health warnings for people being vaccinated against COVID-19 after observing a rise in COVID-19 infections shortly after vaccination, suggesting that many people are letting their...

bmj.com

Covid-19: AstraZeneca vaccine is not linked to increased risk of blood clots, finds European Medicine Agency

Source: BMJ

The Oxford-AstraZeneca COVID-19 vaccine is not linked to an increased risk of blood clots and is both safe and effective, an investigation by the European Medicine Agency (EMA) has concluded....

blogs.bmj.com

Covid-19 vaccine adverse events: balancing monitoring with confidence in vaccines

Source: BMJ

Opinion piece Suspension of the vaccine will have serious implications for vaccine confidence in general and, in particular, for global vaccination programmes. It has already heightened anxiety levels and affected...

blogs.bmj.com

Restoring confidence after the covid-19 Oxford/AstraZeneca vaccine pause will be an uphill battle

Source: BMJ

Opinion piece When a vaccine safety signal is detected, countries face a dilemma: suspend the programme now while investigations establish a causal link, or proceed with vaccinating people amidst fears...

bmj.com

Covid-19: AstraZeneca vaccine is not linked to increased risk of blood clots, finds European Medicine Agency

Source: BMJ

The Oxford-AstraZeneca COVID-19 vaccine is not linked to an increased risk of blood clots and is both safe and effective, an investigation by the European Medicine Agency (EMA) has concluded....

bmj.com

Covid vaccine could be rolled out to children by autumn

Source: BMJ

While the global rollout of vaccines to adults continues apace, with more than 359 million doses of vaccines against SARS-CoV-2 administered as of 15 March, health leaders and researchers have...

bmj.com

Covid-19: What do we know about Sputnik V and other Russian vaccines?

Source: BMJ

Interim results (based on data so far from 14 964 participants in the vaccine group and 4902 in the placebo group) indicate that the vaccine is 91.6% effective, based on its...

bmj.com

Covid-19: WHO says rollout of AstraZeneca vaccine should continue, as Europe divides over safety

Source: BMJ

The WHO and the European Medicines Agency have said that there does not seem to be an increased risk of blood clots with the vaccine and have advised that vaccinations...

africacdc.org

Statement to African Union Member States on the deployment of the AstraZeneca COVID-19 Vaccine to the continent and concerns about adverse event reports coming from Europe

Source: Africa CDC

To date, there has been no causal link established between the administration of the AstraZeneca vaccine and the events reported. Most importantly, the number of blood clots and bleeding disorders...

who.int

WHO statement on AstraZeneca COVID-19 vaccine safety signals

Source: WHO

WHO is in regular contact with the European Medicines Agency and regulators around the world for the latest information on COVID-19 vaccine safety. At this time, WHO considers that the...

who.int

Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on safety signals related to the AstraZeneca COVID-19 vaccine

Source: WHO

The AstraZeneca COVID-19 vaccine (including Covishield) continues to have a positive benefit-risk profile, with tremendous potential to prevent infections and reduce deaths across the world. The available data do not...

afro.who.int

WHO Gambia Officially Hands Over Medical Supplies Worth USD 1 Million For COVID-19 Response

Source: WHO Africa

The WHO handed over medical supplies to the Ministry of Health of the Gambia, at Central Medical Stores, Banjul on the 16th March, 2021. The medical supplies donated on the...

afro.who.int

Africa’s COVID-19 vaccination gains pace, nearly 7 million doses given

Source: WHO Africa

Altogether, 38 African countries have received more than 25 million COVID-19 vaccines and 30 have started vaccination campaigns. Through the COVAX initiative – which is co-led by the Coalition for...

afro.who.int

Nigerian health workers take country’s first COVID-19 vaccine

Source: WHO Africa

The first phase of Nigeria’ national vaccination campaign targets healthcare workers and support staff, first responders and security agencies. Nigeria is slated to receive 84 million doses of the COVID-19...

afro.who.int

What is Africa’s vaccine production capacity?

Source: WHO Africa

COVID-19 vaccination in Africa is gathering pace, with more than 7 million doses so far administered. But the continent received vaccines later than other regions of the world and in...

nejm.org

SARS-CoV-2 Infection after Vaccination in Health Care Workers in California

Source: NEJM

Opinion piece From December 16, 2020, through February 9, 2021, a total of 36,659 health care workers received the first dose of vaccine, and 28,184 of these persons (77%) received...

thelancet.com

National differences in vaccine hesitancy: a concern for the external validity of vaccine studies

Source: The Lancet

WHO named vaccine hesitancy as one of the top ten threats to global health in 2019; they identified complacency, convenience, and lack of confidence as key reasons underlying vaccine hesitancy....

thelancet.com

Operation Warp Speed: implications for global vaccine security

Source: The Lancet

Open access article In showing safety and efficacy of SARS-CoV-2 vaccines and preparing companies for large-scale manufacturing, the US programme called Operation Warp Speed (OWS) has, by accident or design,...

thelancet.com

Communication combats hesitancy

Source: The Lancet

Opinion piece With COVID-19 vaccination programmes now underway in many countries, patients' concerns have shifted toward questions about the vaccines and whether they are safe for them to receive. The...

thelancet.com

People with mental illness should be included in COVID-19 vaccination

Source: The Lancet

Opinion piece According to this Occupation Safety and Health, Abu Dhabi health services policy, a person with generalised anxiety disorder, panic disorder, depression, or even stable psychosis could not be...

bmj.com

Covid-19: Officials query data from AstraZeneca’s US vaccine trial

Source: BMJ

Officials from the monitoring board overseeing AstraZeneca’s latest covid-19 vaccine trial expressed concern that data released by the company this week may have been out of date and “provided an...

blogs.bmj.com

Bringing covid-19 vaccines to high risk populations—like those who are homeless—requires a tailored approach

Source: BMJ

Opinion piece Ensuring effective access to vaccinations for people experiencing homelessness is essential to protecting public health and safeguarding the health of a vulnerable, yet often overlooked population. Achieving this...

bmj.com

Covid-19: variants and vaccination

Source: BMJ

SARS-CoV-2 has been in the human population for more than a year now, causing severe disease in some and resulting in a pandemic that continues to put severe strain on...

bmj.com

Covid-19: Vaccine hesitancy fell after vaccination programme started

Source: BMJ

Preliminary findings from University College London’s Virus Watch study suggest that 86% of those who were unsure about having the vaccine or planned to refuse it in December 2020 have...

england.nhs.uk

Maximising vaccine uptake in underserved communities: a framework for systems, sites and local authorities leading vaccination delivery

Source: NHS

This document provides a problem-solving framework, best practice, and practical guidance for implementing a range of interventions to ensure equitable access to COVID-19 vaccination and drive uptake in underserved communities.

cdc.gov

COVID-19 Vaccines that Require 2 Shots

Source: US CDC

If you receive a Pfizer-BioNTech or Moderna COVID-19 vaccine, you will need 2 shots to get the most protection. You should get your second shot even if you have side...

who.int

WHO supports COVID-19 vaccine rollout, highlights women in health and boosts telemedicine during the pandemic thanks to donors

Source: WHO

COVAX vaccine shipments are beginning to reach countries in need, WHO celebrated International Women’s Day and telemedicine is showing promise for chronic conditions during COVID-19.

who.int

Joint Statement on prioritization of COVID-19 vaccination for seafarers and aircrew

Source: WHO

Seafarers and aircrew need to be protected through vaccination as soon as possible, to facilitate their safe movement across borders. WHO also calls on governments to identify and prepare for...

who.int

COVAX updates participants on delivery delays for vaccines from Serum Institute of India (SII) and AstraZeneca

Source: WHO

The COVAX Facility has notified participating economies that deliveries of doses from the Serum Institute of India (SII) will be delayed in March and April. Separately, participating economies in the...

who.int

Medical Product Alert N°2/2021: Falsified COVID-19 Vaccine BNT162b2

Source: WHO

This WHO Medical Product Alert reports on a falsified COVID-19 Vaccine identified as “BNT162b2” detected in Mexico in February 2021 and recently confirmed as falsified to the WHO. This falsified...

afro.who.int

WHO urges equitable COVID-19 vaccine access to widen reach in Africa

Source: WHO Africa

Africa urgently needs more COVID-19 vaccine supplies as deliveries begin to slow down and initial batches are nearly exhausted in some countries. The continent has so far administered 7.7 million...

nejm.org

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2

Source: NEJM

Report on a phase 3 clinical trial of the mRNA-1273 vaccine against SARS-CoV-2, providing information on immediate injection-site reactions, which were observed in 84.2% of the participants after the first...

nejm.org

Scaling Up Covid-19 Vaccination in Africa — Lessons from the HIV Pandemic

Source: NEJM

Opinion piece Concerns regarding access to Covid-19 vaccines in Africa are reminiscent of concerns raised about responding to the HIV pandemic in the mid-1990s and early 2000s, when highly active...

jwatch.org

Outcomes in Solid-Organ Transplant Recipients After the First Dose of Either SARS-CoV-2 mRNA Vaccine

Source: NEJM

Report on peer reviewed article While no safety issues arose, only 17% of transplant recipients developed detectable antibodies to the SARS-CoV-2 spike protein after immunisation. Immunosuppressed patients generally respond less...

jwatch.org

Pfizer-BioNTech COVID-19 Vaccine 100% Efficacious in Children Aged 12 to 15

Source: NEJM

The Pfizer-BioNTech COVID-19 vaccine already in use among adults has shown "100% efficacy and robust antibody responses" in adolescents between the ages of 12 and 15, the manufacturers announced on...

jwatch.org

Lessons from COVID-19 Vaccination Programs in Healthcare Workers

Source: NEJM

Report on peer reviewed article The studies from Israel, Texas, and California illustrate the dramatic reductions in SARS-CoV-2 infections among health care workers following vaccination (and the results are congruent...

jwatch.org

COVID-19 Vaccines: Pfizer-BioNTech Efficacy at 6 Months / Moderna Variant Trial / J&J Delay

Source: NEJM

The Pfizer-BioNTech COVID-19 vaccine has 91.3% efficacy against symptomatic illness diagnosed from 1 week to 6 months after the second dose of vaccine, the companies reported on Thursday.  A version...

thelancet.com

Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study

Source: The Lancet

The most effective vaccination strategy for reducing mortality due to COVID-19 depends on the time course of the pandemic in the population. For later vaccination start dates, use of SARS-CoV-2...

bmj.com

Covid vaccine: Prioritise over 16s living with immunosuppressed adults, says JCVI

Source: BMJ

People aged 16 or over who live with immunosuppressed adults should be prioritised for covid-19 vaccination alongside priority group 6 (people aged 16 to 65 who have a clinical condition...

bmj.com

Covid-19: Pfizer reports 100% vaccine efficacy in children aged 12 to 15

Source: BMJ

The Pfizer-BioNTech covid-19 vaccine has shown 100% efficacy against SARS-CoV-2 in 12 to 15 year olds in the preliminary results of a phase III trial.

bmj.com

Covid-19: EMA defends AstraZeneca vaccine as Germany and Canada halt rollouts

Source: BMJ

The Oxford AstraZeneca Covid-19 vaccine is facing a further wave of scepticism and restrictions as Canada and Germany halt its use in younger patients, citing reports of clotting disorders in...

bmj.com

Covid-19: Moderna and Pfizer vaccines prevent infections as well as symptoms, CDC study finds

Source: BMJ

Vaccination with the Pfizer or Moderna vaccine reduces infections by 90%, while a single dose confers 80% protection, shows a study led by the US Center for Disease Control and...

england.nhs.uk

Vaccination of adult household contacts of severely immunosuppressed individuals alongside JCVI priority Cohort 6 and completion of Cohorts 1-9

Source: NHS

Advice that adult household contacts of adults (over 16 years of age) with severe immunosuppression should be offered access to COVID-19 vaccination alongside priority group 6 (people aged 16 to...

cdc.gov

Information About Johnson & Johnson’s Janssen COVID-19 Vaccine

Source: US CDC

An overview of the Johnson and Johnson’s, Janseen Covid-19 Vaccine.

cdc.gov

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021

Source: US CDC

Pre-release peer review article Under real-world conditions, mRNA vaccine effectiveness of full immunization (≥14 days after second dose) was 90% against SARS-CoV-2 infections regardless of symptom status; vaccine effectiveness of...

cdc.gov

Science Brief: Background Rationale and Evidence for Public Health Recommendations for Fully Vaccinated People

Source: US CDC

While some prevention measures will continue to be necessary regardless of vaccination status, fully vaccinated people without immunocompromising conditions that may reduce their response to vaccination may be able to...

who.int

Standardization of vaccines for coronavirus disease (COVID-19)

Source: WHO

The listing explains how current WHO written standards may provide useful guidance and information for the development, production and evaluation of candidate COVID-19 vaccines.

who.int

The J&J COVID-19 vaccine: What you need to know

Source: WHO

The WHO Strategic Advisory Group of Experts (SAGE) on Immunisation has issued Interim recommendations for the use of the Janssen Ad26.CoV2.S vaccine against COVID-19. The vaccine is safe and effective...

who.int

Side Effects of COVID-19 Vaccines

Source: WHO

COVID-19 vaccines are safe, and getting vaccinated will help protect you against developing severe COVID-19 disease and dying from COVID-19. You may experience some mild side effects after getting vaccinated,...

who.int

Getting the COVID-19 Vaccine

Source: WHO

Vaccines are a critical tool in the battle against COVID-19, and getting vaccinated is one of the best ways to protect yourself and others from COVID-19. Getting vaccinated is safer...

who.int

Safety of COVID-19 Vaccines

Source: WHO

This article is part of a series of explainers on vaccine development and distribution.  Vaccine safety is one of WHO’s highest priorities, and we’re working closely with national authorities to...

fullfact.org

What’s going on with the AstraZeneca vaccine?

Source: Full Fact

In the period up until 31 March, 20.2 million doses of the AstraZeneca vaccine had been given in the UK, and the Medicines and Healthcare products Regulatory Agency (MHRA) received...

fullfact.org

Why you can’t compare deaths after a positive Covid-19 test with deaths after a vaccine

Source: Full Fact

The answer is that both types of death are assessed by a doctor, and they are quite different.

snopes.com

No, Pfizer’s CEO Did Not Refuse to Take the COVID-19 Vaccine

Source: Snopes

Claim:  Pfizer CEO Albert Bourla refused to take the Pfizer-BioNTech COVID-19 vaccine. Rating: False. Bourla has taken the vaccine.

health.go.ke

CS Kagwe Briefs Media on the Update of COVID-19

Source: KKMoH

During the briefing the Health Cabinet Secretary announced that National Emergency Response Committee on Coronavirus have decided to terminate licenses for importation and administration of COVID-19 vaccinations by the private...

jwatch.org

COVID-19 Outcomes in Pregnancy

Source: NEJM

Report on peer review article It is recommended to administer SARS-CoV-2 vaccination for pregnant people to protect both mother and neonate. We know that, during pregnancy, vaccines against infections such...

jwatch.org

COVID-19 Vaccines: Graded Dosing Protocol / Antibody Persistence

Source: NEJM

Two patients who required treatment for hypersensitivity reactions to the first dose of the Moderna mRNA COVID-19 vaccine were able to receive their second dose without major complications when it...

jwatch.org

COVID-19 Vaccines: EMA on AstraZeneca & Blood Clots / Variants / April 19

Source: NEJM

The European Medicines Agency stated that the occurrence of thrombosis with thrombocytopenia (blood clots) should be considered a very rare side effect of the AstraZeneca COVID-19 vaccine.

jwatch.org

SARS-CoV-2 Variants B.1.351 and P.1 Can Elude Neutralizing Antibodies

Source: NEJM

Report on peer review article Just as bacterial pathogens can develop antimicrobial resistance necessitating continued evolution of drugs to keep pace, and the dynamics of influenza require annual vaccine modifications,...

nejm.org

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)

Source: NEJM

This research found that 501Y.V2  (also known as B.1.351) elicits robust neutralizing antibody responses against both the original variant and 501Y.V3, which indicates high levels of cross-reactivity. The data indicate...

nejm.org

From Vaccine Nationalism to Vaccine Equity — Finding a Path Forward

Source: NEJM

Opinion Piece

As the global community faces scarce supply, we confront a distressing reality: our current global vaccination rates of roughly 6.7 million doses per day translate to achieving herd immunity...

nejm.org

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Source: NEJM

Ongoing studies are monitoring immune responses beyond 6 months as well as determining the effect of a booster dose to extend the duration and breadth of activity against emerging viral...

nejm.org

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Source: NEJM

A single dose of mRNA vaccine elicited rapid immune responses in seropositive participants, with post vaccination antibody titers that were similar to or exceeded titers found in seronegative participants who...

nejm.org

Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2

Source: NEJM

The BNT162b2 vaccine was shown to have 95% efficacy against coronavirus disease 2019 (Covid-19).1 To date, the two-dose vaccine protocol has not been approved in Israel for persons previously infected...

nejm.org

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

Source: NEJM

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant B.1.429 (also called CAL.20C or 452R.V1), first identified in California. The results of this study, and the high efficacy shown by...

nejm.org

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Source: NEJM

Peer review article Although rare, vaccine-induced immune thrombotic thrombocytopenia (VITT) is a new phenomenon with devastating effects for otherwise healthy young adults and requires a thorough risk–benefit analysis. The findings...

nejm.org

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Source: NEJM

Peer review article Vaccination with ChAdOx1 nCov-19 can result in the rare development of immune thrombotic thrombocytopenia mediated by platelet-activating antibodies against PF4, which clinically mimics autoimmune heparin-induced thrombocytopenia.

thelancet.com

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation

Source: The Lancet

Emerging variants of SARS-CoV-2 can evade neutralising antibodies induced by previous infection or vaccination through mutations in the spike protein, including the receptor-binding domain. Vaccinations should induce the highest neutralisation...

thelancet.com

Ramadan and COVID-19 vaccine hesitancy—a call for action

Source: The Lancet

Opinion piece Ramadan fasts require Muslims to abstain from food and drink during daylight hours (exemptions include ill-health). Fasting during Ramadan also requires “refraining from anything entering the body cavities”....

thelancet.com

Correlates of protection from SARS-CoV-2 infection

Source: The Lancet

Report on peer review article The findings of the authors suggest that infection and the development of an antibody response provides protection similar to or even better than currently used...

bmj.com

Covid-19: All Johnson and Johnson vaccine in use is safe, says US regulator

Source: BMJ

The acting head of the US Centers for Medicare and Medicaid Services gave reassurances on 5 April that the Johnson & Johnson vaccine was safe, after a mix-up at a...

blogs.bmj.com

Linda Bauld: Maintaining trust in the covid-19 vaccine programme will be essential in the months ahead

Source: BMJ

Opinion piece In light of recent concerns about the Oxford/AstraZeneca vaccine, sustained and clear communication from trusted sources is needed to maintain uptake as the evidence evolves.

bmj.com

AstraZeneca vaccine: Blood clots are “extremely rare” and benefits outweigh risks, regulators conclude

Source: BMJ

Among more than 20 million people who have been vaccinated with the AstraZeneca vaccine in the UK so far, 79 cases of rare blood clots with low platelets have been...

bmj.com

What do we know about China’s COVID-19 vaccines?

Source: BMJ

There are about a dozen Chinese vaccine candidates for COVID-19, but five front runners have received emergency use approval in China as well as several other countries. At the time...

blogs.bmj.com

Covid-19: The lack of vaccine trial data creates another layer of inequality

Source: BMJ

Opinion piece The COVID-19 vaccine race has highlighted the importance of the equitable distribution of resources worldwide for ethical and epidemiological reasons. Letting the virus run free in low and...

who.int

COVAX reaches over 100 economies, 42 days after first international delivery

Source: WHO

The COVAX Facility has now delivered life-saving vaccines to over 100 economies since making its first international delivery to Ghana on 24 February 2021. So far, more than 38 million...

afro.who.int

Less than 2% of world’s COVID-19 vaccines administered in Africa

Source: WHO Africa

Less than 2% of the 690 million COVID-19 vaccine doses administered to date globally have been in Africa, where most countries received vaccines only five weeks ago and in small...

nejm.org

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Source: New England Journal of Medicine

This correspondence provides follow-up data on the immune response triggered by the Moderna vaccine (mRNA-1273) 119 days after the first vaccine dose (and 3 months after the second dose). The...

nejm.org

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Source: New England Journal of Medicine

This paper describes results of phase 3 clinical trials of the Moderna COVID-19 vaccine (mRNA-1273), which uses mRNA technology targeting the spike protein. Over 30,000 participants were enrolled, receiving two...

thelancet.com

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Source: The Lancet

This paper describes the results of phase 2/3 trials of the Oxford-AstraZeneca vaccine. In this case, the trial primarily assessed vaccine safety, with a particular focus on those aged 70+....

who.int

Extraordinary meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) – 5 January 2021

Source: WHO

This page contains details of the SAGE meeting held on 05/01/2021, where the Pfizer-BioNTech and other COVID-19 vaccines were discussed. As of 04/01/2021, there are a total of 291 vaccine...

thelancet.com

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Source: The Lancet

This paper describes results of four clinical trials of the Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19 (AZD1222)). These clinical trials spanned multiple phases across three countries. This study looks at both...

thelancet.com

Oxford–AstraZeneca COVID-19 vaccine efficacy

Source: The Lancet

There were 58 SARS-CoV-2 vaccines in clinical trials in 2020. Trial data for the Oxford-AstraZeneca vaccine were published in December describing results from four randomised controlled trials in South Africa,...

nejm.org

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

Source: New England Journal of Medicine

This paper describes results of phase 1/2a trials of the Janssen COVID-19 vaccine (Ad26.COV2.S). This vaccine targets the spike protein using a viral vector. The main objective of this trial...

nejm.org

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Source: New England Journal of Medicine

This paper describes the results of the phase 1 trials of two Pfizer-BioNTech COVID-19 vaccine candidate (BNT162b1 and BNT162b2). BNT162b1 targets the receptor-binding domain, whereas the BNT162b2 targets the spike...

nejm.org

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Source: New England Journal of Medicine

This paper describes the results of phase 2/3 trials of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2). Around 40,000 people participated in these trials - half of which received the vaccine (two...

thelancet.com

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Source: The Lancet

This paper describes results of phase 1/2 trials of two vaccine candidates developed by Gamaleya in the Russian Federation. Both vaccines target the spike protein using a viral vector, one...

thelancet.com

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Source: The Lancet

This paper describes the results of phase 1/2 trials of the Sinovac COVID-19 vaccine (CoronaVac), which contains an inactivated form of SARS-CoV-2. Over 700 participants were enrolled on these trials,...

who.int

26th WHO Regulatory Update on COVID-19

Source: WHO

The WHO has granted Emergency Use Listing to the Pfizer-BioNTech COVID-19 vaccine and has issue policy recommendations on how best to use it. This includes a recommendation that the vaccine...

bmj.com

Covid-19 vaccination: What’s the evidence for extending the dosing interval?

Source: BMJ

The UK government has announced that the second doses of COVID-19 vaccines will be administered around 12 weeks after the first, rather than 3-4 weeks which was recommended. This is...

bmj.com

Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination

Source: BMJ

Doctors in Norway are being asked to more thoroughly evaluate the conditions of very frail, elderly patients who have yet to receive COVID-19 vaccinations. This request comes after 23 people...

africacdc.org

COVID-19 Scientific and Public Health Policy Update – (01 December 2020)

Source: Africa CDC

This update provides a summary of the latest developments in scientific knowledge and public health policy from around the world. Highlights on vaccines are summarised below: - Bharat Biotech announced...

thelancet.com

COVID-19 vaccine trials in Africa

Source: The Lancet

Vaccine development and trials were identified as a key research priority for COVID-19 in Africa. The African Academy of Sciences (AAS) Clinical Trials Community has said that globally, only 2%...

who.int

Coronavirus Update 37: What we know about COVID-19 vaccine development

Source: WHO

This presentation gives a brief general overview of vaccine technologies, steps in vaccine development and timelines (both of traditional and accelerated development), and the COVID-19 vaccine candidates in Phase 3...

africacdc.org

COVID-19 Scientific and Public Health Policy Update – (15 December 2020)

Source: Africa CDC

This update provides a summary of the latest developments in scientific knowledge and public health policy from around the world. Highlights on vaccines are summarised below: - The UK government...

who.int

Draft landscape of COVID-19 candidate vaccines

Source: WHO

This document summarises the COVID-19 vaccine candidate landscape, including stages of development and clinical trial data where available. It is updated every Tuesday and Friday. As of 19/01/2021, 64 vaccines...

fullfact.org

No evidence aluminium in vaccines causes Alzheimer’s disease

Source: Full Fact

Claim: Aluminium in vaccines can cause Alzheimer’s disease. Finding: False No link between Alzheimer’s disease and the small amount of aluminium found in some vaccines has been established. Small amounts...

fullfact.org

There’s no evidence that mercury-based chemicals in a Covid-19 vaccine would cause harm

Source: Full Fact

Claim: New Covid-19 vaccines contain levels of mercury that cause brain damage. Finding: False Most commonly given vaccines in the UK do not contain the mercury-based chemical thiomersal. We don’t...

fullfact.org

Claims about the Pfizer Covid-19 vaccine ingredients lack evidence

Source: Full Fact

Claim: The formation of “non-neutralizing antibodies” can lead to an exaggerated immune reaction to vaccines, especially when the person is confronted with the real, “wild” virus after vaccination. This so-called...

fullfact.org

There’s no evidence the Pfizer vaccine interferes with the placenta

Source: Full Fact

Claim: The Pfizer vaccine contains syncytin-1 which is vital for the formation of human placenta, so could lead to infertility. Finding: Mixture The vaccine contains instructions on how to build...

fullfact.org

Some on the Pfizer vaccine trials did get Bell’s palsy, but not more than we’d expect by chance

Source: Full Fact

Claim: Four volunteers developed Bell's palsy after receiving Pfizer's Covid-19 vaccine. Finding: Mixture Whilst this is true, the figure is roughly the level anticipated in a group of this size....

africacheck.org

No, US nurse Tiffany Dover not killed by Covid-19 vaccine

Source: Africa Check

Claim: that Tiffany Dover, a nurse from Tennessee in the United States, fainted and died after receiving her first dose of the Pfizer COVID-19 vaccine. Finding: False The nurse did...

africacheck.org

Yes, Australia abandoned Covid-19 vaccine after false positive HIV test results

Source: Africa Check

Claim: “Australia abandons vaccine attempt, after the shot wrongly gave some people positive HIV test results", from the website, Business Insider Finding: True The vaccine did give people false positive...

snopes.com

Did 23 People In Norway Die After Receiving COVID Vaccine?

Source: Snopes

Claim: Twenty-three people in Norway died as a result of receiving the COVID-19 vaccine. Finding: Unproven 23 people across Norway died since the vaccination programme began; they were vaccinated with...

snopes.com

Is the 1950s ‘Thalidomide Tragedy’ Indicative of COVID-19 Vaccine Risks?

Source: Snopes

Claim: A rapidly approved drug known as thalidomide was not rigorously tested before being prescribed to pregnant women, ultimately leading to “malformations in newborns” to women who were prescribed the...

snopes.com

Did Brazil’s President Bolsonaro Imply COVID-19 Vaccine Turns People Into Crocodiles?

Source: Snopes

Brazilian President Jair Bolsonaro said, “In the Pfizer contract it's very clear: 'we're not responsible for any side effects.' If you turn into a crocodile, it's your problem.” Finding: Correct...

snopes.com

Does Pfizer ‘Page 132’ Warn Against Unprotected Sex After COVID-19 Vaccine?

Source: Snopes

Claim: Pfizer vaccine "page 132" warns not to have unprotected sex for 28 days after the second dose of the COVID-19 vaccine because "genetic manipulation" may cause birth defects. Finding:...

snopes.com

Did Doctors Recommend Genital COVID-19 Vaccination Injections for Men?

Source: Snopes

Claim: Two scientific studies found that men should inject the COVID-19 vaccine into the penis, and that the vaccine increased penis size among some men. Finding: False The pictures shared...

snopes.com

Did a Portuguese Nurse Die Two Days After COVID-19 Vaccination?

Source: Snopes

Claim: A Portuguese nurse named Sonia Azevedo died from adverse side effects from the Pfizer-BioNTech COVID-19 vaccine. This was first published by India-based news-outlet WION (World Is One News) and...

fullfact.org

There are no human cells in the AstraZeneca vaccine, and it won’t give you a chimpanzee virus

Source: Full Fact

WHAT WAS CLAIMED The Oxford/AstraZeneca vaccine contains viruses from chimpanzees. OUR VERDICT The vaccine uses a modified virus which was originally created from a virus found in chimpanzees.

fullfact.org

There is evidence vaccines reduce risk of Covid-19 illness

Source: Full Fact

WHAT WAS CLAIMED Vaccines don’t stop you getting COVID-19 or spreading it. OUR VERDICT The Pfizer and AstraZeneca COVID-19 vaccines reduce your chances of getting sick with Covid-19. There’s some...

jwatch.org

COVID-19 Vaccines: Reassuring Safety Data / 1 Shot If You’ve Had COVID?

Source: NEJM

A CDC analysis of adverse event data during the first month of COVID-19 vaccination in the U.S. offers reassurance on use of the two authorized mRNA vaccines.  A New York...

jwatch.org

FDA Offers Guidance to Vaccine, Therapeutics Companies on SARS-CoV-2 Variants

Source: NEJM

The FDA has published guidance regarding SARS-CoV-2 variants for companies making vaccines, treatments, and diagnostic tests.

jwatch.org

Will the Current mRNA COVID-19 Vaccines Work Against SARS-CoV-2 Variants?

Source: NEJM

Report on research article These findings suggest that the B.1.351 variant (and others harbouring similar mutations) is less sensitive to vaccine-induced antibodies than earlier SARS-CoV-2 lineages, including B.1.117. However, vaccines...

jwatch.org

Pfizer-BioNTech Studying a COVID-19 Vaccine Booster

Source: NEJM

Pfizer and BioNTech said on Thursday that they will begin studying whether a third dose of their authorized mRNA vaccine is safe and effective against currently circulating and emerging strains...

nejm.org

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Source: NEJM

Peer reviewed article This study estimates a high effectiveness of the BNT162b2 vaccine for preventing symptomatic COVID-19 in a non-controlled setting, similar to the vaccine efficacy reported in the randomized...

thelancet.com

Feelings towards COVID-19 vaccination in Africa

Source: The Lancet

Opinion piece The global north has started immunising large numbers of people against SARS-CoV-2 before the global south,  Africans concerned about COVID-19 vaccine safety might be reassured by this track...

thelancet.com

Bell’s palsy and SARS-CoV-2 vaccines

Source: The Lancet

Opinion piece There have been many studies around the influenza vaccine and Bell's palsy.  There is a call for robust surveillance for potential mRNA vaccine-associated Bell's palsy, we also note...

thelancet.com

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

Source: The Lancet

Response to peer reviewed article Further evidence that the vaccine still generates a strong immune response in people who have previously been infected with SARS-CoV-2.

thelancet.com

Migrant health is public health: a call for equitable access to COVID-19 vaccines

Source: The Lancet

Opinion piece Migrant and displaced communities—regardless of their legal status—urgently need to be explicitly and proactively included in vaccination plans.  This action not only recognises the interdependence between migrant health...

thelancet.com

Historical evidence to inform COVID-19 vaccine mandates

Source: The Lancet

Opinion piece Most countries have a mandatory vaccination programme for childhood vaccinations, with varying strategies for enforcement that might establish precedent. If strategies of persuasion do not achieve adequate vaccination...

thelancet.com

Covid-19 vaccine apps should deliver more to patients

Source: The Lancet

Opinion piece Digital tools for side-effect surveillance emphasise data collection over providing user feedback, and public misperceptions might influence what is reported and the causal attributions.  Preliminary evidence shows that...

bmj.com

Covid-19: Pfizer BioNTech vaccine reduced cases by 94% in Israel, shows peer reviewed study

Source: BMJ

Peer reviewed article Peter English, consultant in communicable disease control and past chair of the BMA’s Public Health Medicine Committee, said, “This is more great news, confirming that the vaccine...

bmj.com

Covid-19: Plans to share vaccines aren’t enough, says charity

Source: BMJ

Opinion piece New pledges by leaders of the G7 group of richest countries to intensify cooperation on COVID-19 and commit $7.5bn (£5.3bn; €6.2bn) to sharing supplies of vaccine around the...

cdc.gov

What to Expect after Getting a COVID-19 Vaccine

Source: US CDC

COVID-19 vaccination will help protect you from getting COVID-19. You may have some side effects, which are normal signs that your body is building protection, and this article explains them.

cdc.gov

Frequently Asked Questions about COVID-19 Vaccination

Source: US CDC

Answers to commonly asked questions about COVID-19 vaccination. CDC also has information for busting common vaccine myths available in facts about COVID-19 vaccines.

cdc.gov

Selected Adverse Events Reported after COVID-19 Vaccination

Source: US CDC

COVID-19 vaccines are safe and effective. Rare adverse events described on this page have been reported

cdc.gov

What to Do if You Have an Allergic Reaction After Getting A COVID-19 Vaccine

Source: US CDC

If you had a severe allergic reaction after getting the first dose of an mRNA COVID-19 vaccine, CDC recommends that you should not get the second dose. If you had...

cdc.gov

National Forum on COVID-19 Vaccine: Finale

Source: US CDC

A video explaining how to grow confidence and trust in the vaccine.

cdc.gov

Reduction in COVID-19 Patients Requiring Mechanical Ventilation Following Implementation of a National COVID-19 Vaccination Program — Israel, December 2020–February 2021

Source: US CDC

Pre release article Clinical trials have demonstrated the efficacy of COVID-19 vaccines in a controlled setting. Israel initiated a national vaccination campaign in December 2020, prioritizing persons aged >60 years...

afro.who.int

What is COVID-19 vaccine efficacy?

Source: WHO Africa

COVID-9 vaccines have been developed within less than a year after the vi1rus was first detected. Several vaccines that have become available have shown different levels of efficacy, this article...

snopes.com

The COVID-19 vaccine is not recommended for pregnant women unless they are at high risk of exposure

Source: Snopes

Claim: The World Health Organisation warned that pregnant women should avoid the COVID-19 vaccination. Partly true As of January 2021, the World Health Organization (WHO) said that the use of...

kemri.org

ChAdOx1 nCOV -19 Vaccine Trial

Source: KeMRI

The article provides details of the trial of the ChAdOx1 vaccine for COVID-19  currently being conducted in Kenya. The trial aims to assess whether the ChAdOx1 vaccine is safe, effective...

thelancet.com

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

Source: Lancet

. A vaccine targeting a new part of the SARS CoV-2 spike protein (the protrusions that give the virus the name coronavirus as they look like a crown) have proved...

thelancet.com

Next-generation COVID-19 vaccines: here come the proteins

Source: Lancet

Opinion piece by Anna K Blakney,  Michael Smith Laboratories, and Paul F McKay, Imperial College London,  The continued development and use of new technology used to create the RNA (genetic...

thelancet.com

SARS-CoV-2 evolution and vaccines: cause for concern?

Source: Lancet

Opinion Piece by Thomas C Williams, University of Edinburgh and Wendy A Burges, University of Cape Town Most vaccines work by getting our body to recognise and react to a...

snopes.com

Researchers did Warn that Certain COVID-19 Vaccines Could Increase HIV Risk

Source: Snopes

Claim: Researchers warned in The Lancet that a form of COVID-19 vaccine in development (and approved for limited use in China) could potentially increase the risk of acquiring HIV. Mostly...

bmj.com

Covid-19: What new variants are emerging and how are they being investigated?

Source: The BMJ

The new, more transmissible variant of SARS-CoV-2 found in England is just one of many variations of the virus being detected around the world. These include variant P.1 or VOC202101/02,...

afro.who.int

Africa needs timely access to safe and effective COVID-19 vaccines

Source: WHO

The development and approval of safe and effective vaccines less than a year after the emergence of COVID-19 is a stunning achievement. However, in Africa, Guinea is the sole low-income...

who.int

Scientists tackle vaccine safety, efficacy and access at global R&D forum

Source: WHO

More than 2,800 scientists from 130 countries gathered on Friday (January 15) in a virtual forum hosted by the World Health Organization (WHO) to identify knowledge gaps and set research...

fullfact.org

People giving Covid-19 vaccines won’t be tried as war criminals

Source: Full Fact

Claim: We don’t know the Covid-19 vaccines are safe because trials are still underway and won’t finish until 2023. Anyone getting the vaccine is being experimented on. Verdict:  Multiple phases...

jwatch.org

“Sputnik V” Vaccine Found Over 90% Effective Against COVID-19

Source: NEJM

Summary article  A Russian vaccine against COVID-19 — Gam-COVID-Vac (dubbed "Sputnik V") — shows 92% efficacy in interim results from a phase 3 trial reported in The Lancet. The two-dose...

ecdc.europa.eu

Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA

Source: ECDC

This report provides an updated overview of national COVID-19 vaccination rollout across the EU/EEA, including new insights into some of the critical aspects and challenges Member States are experiencing with...

ecdc.europa.eu

Stress test on logistical aspects of COVID-19 vaccination deployment plans: final report

Source: ECDC

The ECDC, together with the European Commission’s Directorate-General for Health and Food Safety, organised a stress test of the logistical aspects of COVID-19 vaccination deployment plans. Twelve EU/EEA Member States...

thelancet.com

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Source: The Lancet

A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials. This...

thelancet.com

WHO international non-proprietary names: the need to distinguish COVID-19 vaccines

Source: The Lancet

Opinion piece  The WHO International Non-proprietary Names Programme would like to highlight that international non-proprietary names (INNs), assigned to well defined pharmaceutical substances, including those used in vaccines, ensure that...

thelancet.com

COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics

Source: The Lancet

COVID-19 vaccine acceptance depends on the characteristics of new vaccines and the national vaccination strategy, among various other factors, in the working-age population in France.

thelancet.com

Understanding the determinants of acceptance of COVID-19 vaccines: a challenge in a fast-moving situation

Source: The Lancet

Opinion piece by Pierre Verger, Patrick Peretti-Watel This study shows that most people are probably not absolutely for or against COVID-19 vaccines. Depending on their own profile and preferences, and...

bmj.com

Why aren’t covid-19 vaccines being manufactured in standard prefilled syringes?

Source: BMJ

Opinion piece  This article discusses the difficulties of the final processes when delivering vaccines. It questions why, -given prefilled syringes are the safest and standard recommended delivery device for most...

bmj.com

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

Source: BMJ

News article  The SARS-CoV-2 vaccine produced by the US biotechnology company Novavax is 95.6% effective against the original variant of SARS-CoV-2 but also provides protection against the newer variants B.1.1.7...

bmj.com

Covid-19: AstraZeneca vaccine is approved in EU with no upper age limit

Source: BMJ

News Article  The European Medicines Agency authorised Astra Zeneca’s SARS-CoV-2 vaccine for use in all adults aged over 18 on 29 January. Amid reports that the vaccine had lower efficacy...

bmj.com

Covid-19: New data on Oxford AstraZeneca vaccine backs 12 week dosing interval

Source: BMJ

A news article reporting a preprint paper currently under review at the Lancet. The paper is an analysis of data from vaccine trials involving 17,177 participants in the UK, Brazil,...

cdc.gov

Ensuring the Safety of COVID-19 Vaccines in the United States

Source: US CDC

Clinical trials and vaccine safety monitoring are being conducted to evaluate additional COVID-19 vaccines in many thousands of study participants. These trials will generate scientific data and other information that...

afro.who.int

COVAX expects to start sending millions of COVID-19 vaccines to Africa in February

Source: Afro WHO

COVAX has notified countries in Africa of the estimated dose allocation for the first phase of COVID-19 vaccine delivery. The global initiative led by the WHO, Gavi the Vaccine Alliance...

bmj.com

Covid-19: India is at centre of global vaccine manufacturing, but opacity threatens public trust

Source: BMJ

Article by freelance journalist Kamala Thiagarajan.  On 3 January, India’s top drug regulator issued emergency approval for two vaccines for restricted use against Covid-19, even though phase III clinical trials...